{"content":"<li class=\"n-box-item date-title\" data-end=\"1513141199\" data-start=\"1513054800\" data-txt=\"Monday, December 23, 2019\">Tuesday, December 12, 2017</li><li class=\"n-box-item sa-box-item\" data-id=\"3317906\" data-ts=\"1513124178\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IRM\" target=\"_blank\">IRM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317906-iron-mountain-prices-14_5m-share-offering-37-share\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Iron Mountain prices 14.5M-share offering at $37/share</a></h4><ul>   <li>Iron Mountain (NYSE:<a href='https://seekingalpha.com/symbol/IRM' title='Iron Mountain Inc.'>IRM</a>), which <font color='red'>fell 7.2%</font> today after <a href=\"https://seekingalpha.com/news/3317630-iron-mountain-buy-u-s-operations-io-data-centers-1_32b\" target=\"_blank\">commencing a public offering</a> to buy U.S. operations of IO Data Centers, has <a href=\"https://seekingalpha.com/pr/17025383-iron-mountain-incorporated-prices-common-stock-offering\" target=\"_blank\">priced the offering</a>.</li>    <li>The 14.5M-share offering will go at $37/share. Shares are <font color='red'>down 0.2%</font> postmarket to $37.71.</li>    <li>Underwriters have a 30-day option to buy up to an additional 2.175M shares at the offering price.</li>    <li>Net proceeds along with those from an offering of 5.25% senior notes due 2028 and cash on hand will go to finance the purchase of IO Data Centers.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3317906\" data-linked=\"Iron Mountain prices 14.5M-share offering at $37/share\" data-tweet=\"$IRM - Iron Mountain prices 14.5M-share offering at $37/share https://seekingalpha.com/news/3317906-iron-mountain-prices-14_5m-share-offering-37-share?source=tweet\" data-url=\"https://seekingalpha.com/news/3317906-iron-mountain-prices-14_5m-share-offering-37-share\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:16 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317901\" data-ts=\"1513119077\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MLNX\" target=\"_blank\">MLNX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317901-mellanox-recoups-losses-on-new-positive-launch-susquehanna\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mellanox recoups some losses on New Positive launch at Susquehanna</a></h4><ul>   <li>Mellanox Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/MLNX' title='Mellanox Technologies, Ltd.'>MLNX</a>) is making up some of the day's decline, <font color='green'>up 0.8%</font> after hours, after a New Positive launch at Susquehanna.</li>    <li>The firm has set its price target at an above-average $75, implying 24.4% upside from today's close.</li>    <li>Shares <font color='red'>dropped 2.8%</font> today; they're <font color='green'>up 49%</font> in 2017 and hit a 52-week high of $63.20 on Friday.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3317901\" data-linked=\"Mellanox recoups some losses on New Positive launch at Susquehanna\" data-tweet=\"$MLNX - Mellanox recoups some losses on New Positive launch at Susquehanna https://seekingalpha.com/news/3317901-mellanox-recoups-losses-on-new-positive-launch-susquehanna?source=tweet\" data-url=\"https://seekingalpha.com/news/3317901-mellanox-recoups-losses-on-new-positive-launch-susquehanna\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:51 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317898\" data-ts=\"1513118129\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317898-after-hours-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers</a></h4><ul>     <li><b>Top gainers, as of 5.25 p.m.:</b> <a href='https://seekingalpha.com/symbol/RLGY' title='Realogy Holdings'>RLGY</a> <font color='green'>+2.5%</font>. <a href='https://seekingalpha.com/symbol/SN' title='Sanchez Energy Corporation'>SN</a> <font color='green'>+2.1%</font>. <a href='https://seekingalpha.com/symbol/BG' title='Bunge Limited'>BG</a> <font color='green'>+1.8%</font>. <a href='https://seekingalpha.com/symbol/LXFT' title='Luxoft Holding Inc'>LXFT</a> <font color='green'>+1.7%</font>.</li><li><b>Top losers, as of 5.25p.m.:</b> <a href='https://seekingalpha.com/symbol/NAT' title='Nordic American Tankers Limited'>NAT</a> <font color='red'>-15.5%</font>. <a href='https://seekingalpha.com/symbol/PAY' title='VeriFone Systems, Inc.'>PAY</a> <font color='red'>-7.2%</font>. <a href='https://seekingalpha.com/symbol/CIVI' title='Civitas Solutions'>CIVI</a> <font color='red'>-6.6%</font>. <a href='https://seekingalpha.com/symbol/MDB' title='MongoDB, Inc.'>MDB</a> <font color='red'>-6.0%</font>. <a href='https://seekingalpha.com/symbol/PTI' title='Proteostasis Therapeutics'>PTI</a> <font color='red'>-5.9%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3317898\" data-linked=\"After Hours Gainers / Losers\" data-tweet=\"$RLGY $SNEC $BG - After Hours Gainers / Losers https://seekingalpha.com/news/3317898-after-hours-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3317898-after-hours-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:35 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317894\" data-ts=\"1513116871\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WDC\" target=\"_blank\">WDC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317894-western-digital-and-toshiba-announce-agreement-on-chip-unit-fab-6\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Western Digital and Toshiba announce agreement on chip unit, Fab 6</a></h4><ul><li>        Western Digital (NYSE:<a href='https://seekingalpha.com/symbol/WDC' title='Western Digital Corporation'>WDC</a>) and Toshiba (<a href='https://seekingalpha.com/symbol/TOSBF' title='Toshiba Corp.'>OTCPK:TOSBF</a>, <a href='https://seekingalpha.com/symbol/TOSYY' title='Toshiba Corp. ADR'>OTCPK:TOSYY</a>) officially&nbsp;<a href=\"https://seekingalpha.com/pr/17025321-toshiba-western-digital-reach-global-settlement-agree-strengthen-flash-memory-collaboration\" target=\"_blank\">announce</a> a global settlement agreement to resolve the ongoing litigation and arbitration.</li><li>               TMC and Western Digital will participate jointly in future investments in Fab 6, now under construction, including the round announced in October. The companies also plan to enter into agreements for Western Digital&rsquo;s participation in the new flash wafer fab planned for Iwate, Japan.&nbsp;</li><li>                  The parties agree to resolve all outstanding disputes relating to the sale of TMC to the Bain-led consortium. The agreement included mutual protections for assets and IP.    </li><li>               Toshiba, TMC, and Western Digital will drop all pending litigation and arbitration. &nbsp;&nbsp; &nbsp;</li><li>Western Digital shares are&nbsp;<font color='green'>up 1.7%&nbsp;</font>aftermarket.&nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3317650-toshiba-western-digital-settle-chip-spat\" target=\"_blank\">Toshiba, Western Digital settle chip spat</a> (Dec. 12)</li></ul><div class=\"tiny-share-widget\" data-id=\"3317894\" data-linked=\"Western Digital and Toshiba announce agreement on chip unit, Fab 6\" data-tweet=\"$WDC $WDC $TOSBF - Western Digital and Toshiba announce agreement on chip unit, Fab 6 https://seekingalpha.com/news/3317894-western-digital-and-toshiba-announce-agreement-on-chip-unit-fab-6?source=tweet\" data-url=\"https://seekingalpha.com/news/3317894-western-digital-and-toshiba-announce-agreement-on-chip-unit-fab-6\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:14 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>26&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317885\" data-ts=\"1513115645\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MDB\" target=\"_blank\">MDB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317885-mongodbminus-3_5-despite-q3-beats-upside-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MongoDB -3.5% despite Q3 beats, upside guidance</a></h4><ul><li>        MongoDB (NASDAQ:<a href='https://seekingalpha.com/symbol/MDB' title='MongoDB, Inc.'>MDB</a>) shares are&nbsp;<font color='red'>down 3.5%</font>&nbsp;aftermarket despite Q3 results that beat EPS and revenue estimates. Upside Q4 guidance has revenue from $42M to $42.5M (consensus: $41.33M) and EPS from -$0.43 to -$0.42 (consensus: -$0.44).</li><li>               Upside FY18 guidance: revenue, $151.5M to $152M (consensus: $146.14M); EPS, -$1.77 to -$1.76 (consensus: -$1.83).&nbsp;</li><li>               Key metrics: Subscription revenue, $37.9M (+59% Y/Y); Services revenue, $3.6M (+44%); non-GAAP gross margin, 74%; loss from operations, $18.4M; cash and equivalents, $289.1M; FCF, -$10.4M.&nbsp;</li><li>               Customers totaled over 4.9K at quarter&rsquo;s end, up 88% on the year, with 2.6K MongoDB Atlas customers, up 37%.&nbsp;</li><li><a href=\"https://seekingalpha.com/pr/17025220-mongodb-inc-announces-third-quarter-fiscal-2018-financial-results\" target=\"_blank\">Press release&nbsp;&nbsp;</a>&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3317852-mongodb-beats-0_04-beats-revenue\" target=\"_blank\">MongoDB beats by $0.04, beats on revenue</a> (Dec. 12)</li></ul><div class=\"tiny-share-widget\" data-id=\"3317885\" data-linked=\"MongoDB -3.5% despite Q3 beats, upside guidance\" data-tweet=\"$MDB - MongoDB -3.5% despite Q3 beats, upside guidance https://seekingalpha.com/news/3317885-mongodbminus-3_5-despite-q3-beats-upside-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3317885-mongodbminus-3_5-despite-q3-beats-upside-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:54 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317881\" data-ts=\"1513115192\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PTI\" target=\"_blank\">PTI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317881-proteostasis-launches-7m-share-stock-offering-shares-down-8-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Proteostasis launches 7M-share stock offering; shares down 8% after hours</a></h4><ul><li>Proteostasis Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/PTI' title='Proteostasis Therapeutics'>PTI</a>) <a href=\"https://seekingalpha.com/pr/17025213-proteostasis-therapeutics-announces-proposed-public-offering-common-stock\" target=\"_blank\">commences </a>a public offering of 7M shares of common stock. Underwriters over-allotment is an additional 1.05M shares.</li><li>Price and terms have yet to be announced.</li><li>Shares are down&nbsp;<font color='red'>8%</font>&nbsp;after hours on robust volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3317881\" data-linked=\"Proteostasis launches 7M-share stock offering; shares down 8% after hours\" data-tweet=\"$PTI - Proteostasis launches 7M-share stock offering; shares down 8% after hours https://seekingalpha.com/news/3317881-proteostasis-launches-7m-share-stock-offering-shares-down-8-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3317881-proteostasis-launches-7m-share-stock-offering-shares-down-8-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:46 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317866\" data-ts=\"1513113950\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/STM\" target=\"_blank\">STM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317866-stmicroelectronics-acquires-software-development-tools-company\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">STMicroelectronics acquires software development tools company</a></h4><ul><li>        STMicroelectronics (NYSE:<a href='https://seekingalpha.com/symbol/STM' title='STMicroelectronics NV'>STM</a>) <a href=\"https://seekingalpha.com/pr/17025216-stmicroelectronics-acquires-atollic-embedded-systems-company-engineering-integrated\" target=\"_blank\">acquires </a>software development tools specialist Atollic for $7M in cash.</li><li>               The acquisition was funded with available cash and an estimated $1M deferred earn-out contingent on certain conditions.&nbsp;</li><li>               STMicroelectronics shares are&nbsp;<font color='green'>up 0.05%</font>&nbsp;aftermarket.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3317866\" data-linked=\"STMicroelectronics acquires software development tools company\" data-tweet=\"$STM - STMicroelectronics acquires software development tools company https://seekingalpha.com/news/3317866-stmicroelectronics-acquires-software-development-tools-company?source=tweet\" data-url=\"https://seekingalpha.com/news/3317866-stmicroelectronics-acquires-software-development-tools-company\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:25 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317861\" data-ts=\"1513113593\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FATE\" target=\"_blank\">FATE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317861-fate-therapeutics-readies-equity-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fate Therapeutics readies equity offering</a></h4><ul><li>Fate Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/FATE' title='Fate Therapeutics, Inc.'>FATE</a>) <a href=\"https://seekingalpha.com/pr/17025209-fate-therapeutics-announces-proposed-public-offering-common-stock\" target=\"_blank\">launches </a>a public offering of common stock. Price, volume and terms have yet to be announced.</li></ul><div class=\"tiny-share-widget\" data-id=\"3317861\" data-linked=\"Fate Therapeutics readies equity offering\" data-tweet=\"$FATE - Fate Therapeutics readies equity offering https://seekingalpha.com/news/3317861-fate-therapeutics-readies-equity-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3317861-fate-therapeutics-readies-equity-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:19 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317859\" data-ts=\"1513113385\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HMNY\" target=\"_blank\">HMNY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317859-moviepass-owner-announces-share-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MoviePass owner announces share offering</a></h4><ul> <li>Helios and Matheson Analytics (NASDAQ:<a href='https://seekingalpha.com/symbol/HMNY' title='Helios and Matheson Analytics, Inc.'>HMNY</a>)&nbsp;announces a new public offering of shares and       warrants that will be issued separately.</li><li>Details on the size of the offering weren't disclosed.</li><li>The company says that it intends to use the proceeds from the offering to increase its ownership stake in MoviePass and support business operations of the movie ticket subscription platform.</li><li>Source: <a href=\"https://seekingalpha.com/pr/17025207-helios-matheson-analytics-announces-proposed-public-offering-common-stock-warrants\" target=\"_blank\">Press Release</a></li><li>HMNY&nbsp;<font color='red'>-14.19%</font>&nbsp;AH to $8.65.</li></ul><div class=\"tiny-share-widget\" data-id=\"3317859\" data-linked=\"MoviePass owner announces share offering\" data-tweet=\"$HMNY - MoviePass owner announces share offering https://seekingalpha.com/news/3317859-moviepass-owner-announces-share-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3317859-moviepass-owner-announces-share-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:16 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>93&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317846\" data-ts=\"1513112513\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SYNA\" target=\"_blank\">SYNA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317846-synaptics-enters-mass-production-for-in-display-fingerprint-sensor\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Synaptics enters mass production for in-display fingerprint sensor</a></h4><ul><li>        Synaptics (NASDAQ:<a href='https://seekingalpha.com/symbol/SYNA' title='Synaptics Incorporated'>SYNA</a>) <a href=\"https://seekingalpha.com/pr/17024087-synaptics-brings-world-s-first-display-fingerprint-sensors-smartphones-mass-production-top\" target=\"_blank\">announces</a> mass production of its in-display fingerprint sensors with a top five OEM.</li><li>               The Clear ID FS9500 family of optical sensors were designed for infinity displays. The sensors activate only when needed.&nbsp;</li><li>               Synaptics says the top OEM will unveil its phone using the Clear ID sensor at January&rsquo;s CES.&nbsp;</li><li>                  Though Clear ID isn&rsquo;t as fast as direct contact fingerprint sensors, the company does promise it&rsquo;s &ldquo;twice as fast&rdquo; as 3D face recognition. Apple&rsquo;s iPhone X launched without Touch ID and with Face ID &nbsp;due to problems integrating fingerprint sensors into the OLED display.    </li><li>Synaptics shares are&nbsp;<font color='green'>up 2.8%</font>.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3317846\" data-linked=\"Synaptics enters mass production for in-display fingerprint sensor\" data-tweet=\"$SYNA - Synaptics enters mass production for in-display fingerprint sensor https://seekingalpha.com/news/3317846-synaptics-enters-mass-production-for-in-display-fingerprint-sensor?source=tweet\" data-url=\"https://seekingalpha.com/news/3317846-synaptics-enters-mass-production-for-in-display-fingerprint-sensor\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:01 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317841\" data-ts=\"1513111047\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KOS\" target=\"_blank\">KOS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317841-kosmos-energyminus-12-after-coming-up-empty-offshore-mauritania-well\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Kosmos Energy -12% after coming up empty at offshore Mauritania well</a></h4><ul>     <li>Kosmos Energy (<a href='https://seekingalpha.com/symbol/KOS' title='Kosmos Energy'>KOS</a> <font color='red'>-12.1%</font>) is clobbered after saying it will <a href=\"https://seekingalpha.com/pr/17024003-kosmos-energy-provides-update-exploration-drilling-program-offshore-mauritania\" target=\"_blank\">plug and abandon</a> its Lamantin-1 exploration well in Block C-12 offshore Mauritania after it failed to find significant amounts of oil and gas.</li>     <li>\"We are still in the early stages of exploring this newly emerging basin and our forward drilling program remains unchanged given the independent nature of the prospects,\"&nbsp;CEO Andrew Inglis says. \"The drillship will now proceed as planned to test the independent Requin Tigre prospect offshore Senegal, which will be followed by two high-impact oil tests offshore Suriname in mid-2018.\"</li>     <li>Before the&nbsp;Lamantin prospect, KOS had drilled&nbsp;the Hippocampe-1 exploration well offshore&nbsp;Mauritania, which <a href=\"https://seekingalpha.com/news/3306215-kosmos-energy-fails-find-oil-gas-well-mauritania\" target=\"_blank\">also failed to find oil or gas</a>.</li>     <li>KOS is the exploration operator of Block C-12 with 28% equity; <a href='https://seekingalpha.com/symbol/BP' title='BP p.l.c.'>BP</a> is one of its partners, with a 62% ownership stake.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3317841\" data-linked=\"Kosmos Energy -12% after coming up empty at offshore Mauritania well\" data-tweet=\"$KOS $KOS $BP - Kosmos Energy -12% after coming up empty at offshore Mauritania well https://seekingalpha.com/news/3317841-kosmos-energyminus-12-after-coming-up-empty-offshore-mauritania-well?source=tweet\" data-url=\"https://seekingalpha.com/news/3317841-kosmos-energyminus-12-after-coming-up-empty-offshore-mauritania-well\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:37 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317840\" data-ts=\"1513110870\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IRBT\" target=\"_blank\">IRBT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317840-bounce-higher-for-irobot-after-sa-mention\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bounce higher for iRobot after SA mention</a></h4><ul><li>Shares of iRobot (<a href='https://seekingalpha.com/symbol/IRBT' title='iRobot Corporation'>IRBT</a> <font color='green'>+6.2%</font>) track higher on strong volume.</li><li>Some financial websites are attributing the move to a Seeking Alpha positive article from contributor <a href=\"https://seekingalpha.com/article/4131242-irobot-good-stock-robotics-revolution\" target=\"_blank\">MagicDiligence</a>.</li><li>The bouncy trading this year on iRobot includes a 30% decline over the last 90 days.</li></ul><div class=\"tiny-share-widget\" data-id=\"3317840\" data-linked=\"Bounce higher for iRobot after SA mention\" data-tweet=\"$IRBT - Bounce higher for iRobot after SA mention https://seekingalpha.com/news/3317840-bounce-higher-for-irobot-after-sa-mention?source=tweet\" data-url=\"https://seekingalpha.com/news/3317840-bounce-higher-for-irobot-after-sa-mention\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:34 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317837\" data-ts=\"1513109861\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DPW\" target=\"_blank\">DPW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317837-street-sweeper-cautious-on-digital-power\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">The Street Sweeper cautious on Digital Power</a></h4><ul><li>        <a href=\"http://www.thestreetsweeper.org/undersurveillance/Digital_Power_Corporation__DPW___Crypto_Thriller_Turns_Into_Stockholder_Chiller\" target=\"_blank\">The Street Sweeper</a> is out with a cautious report on Digital Power Corporation (NYSEMKT:<a href='https://seekingalpha.com/symbol/DPW' title='DPW Holdings, Inc.'>DPW</a>).</li><li>               The Street Sweeper notes that share prices have jumped up on news Digital Power wants to launch a power system for cryptocurrency mining but doesn&rsquo;t have the product.&nbsp;</li><li>               Also mentioned: Digital Power&rsquo;s new offering of 640K shares, which the Sweeper says will dilute the stock for those jumping in on cryptocurrency hopes. &nbsp;&nbsp;</li><li>               Digital Power shares are still&nbsp;<font color='green'>up 17%</font>.&nbsp;&nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3317837\" data-linked=\"The Street Sweeper cautious on Digital Power\" data-tweet=\"$DPW - The Street Sweeper cautious on Digital Power https://seekingalpha.com/news/3317837-street-sweeper-cautious-on-digital-power?source=tweet\" data-url=\"https://seekingalpha.com/news/3317837-street-sweeper-cautious-on-digital-power\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:17 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>30&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317836\" data-ts=\"1513109694\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BA\" target=\"_blank\">BA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317836-canada-scraps-boeing-deal-talks-tough-on-upcoming-contract-for-88-jets\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Canada scraps Boeing deal, talks tough on upcoming contract for 88 jets</a></h4><ul>     <li><a href=\"https://www.reuters.com/article/us-canada-boeing-fighterjets/canada-makes-clear-boeing-must-back-down-if-it-wants-jet-order-idUSKBN1E62IJ\" target=\"_blank\">Canada officially scraps plans to buy</a> 18 Boeing (<a href='https://seekingalpha.com/symbol/BA' title='The Boeing Company'>BA</a> <font color='green'>+2.9%</font>) fighter jets and reiterates the company would have little chance of winning a larger contract for 88 jets unless it drops a challenge against domestic planemaker Bombardier (<a href='https://seekingalpha.com/symbol/BDRAF' title='Bombardier Inc.A'>OTCQX:BDRAF</a>, <a href='https://seekingalpha.com/symbol/BDRBF' title='Bombardier Inc.B'>OTCQX:BDRBF</a>).</li>     <li>In a clear reference to Boeing, Canada's public works and procurement minister told a news conference today that &ldquo;bidders responsible for harming Canada&rsquo;s economic interests will be at a distinct disadvantage&rdquo; compared to other companies competing for the 88 jets.</li>     <li>If Boeing is excluded, potential winners could include Airbus (<a href='https://seekingalpha.com/symbol/EADSF' title='Airbus SE'>OTCPK:EADSF</a>, <a href='https://seekingalpha.com/symbol/EADSY' title='Airbus SE ADR'>OTCPK:EADSY</a>), Lockheed Martin (NYSE:<a href='https://seekingalpha.com/symbol/LMT' title='Lockheed Martin'>LMT</a>) and Dassault Aviation (<a href='https://seekingalpha.com/symbol/DUAVF' title='DASSAULT AVIATION'>OTCPK:DUAVF</a>).</li></ul><div class=\"tiny-share-widget\" data-id=\"3317836\" data-linked=\"Canada scraps Boeing deal, talks tough on upcoming contract for 88 jets\" data-tweet=\"$BA $BA $BDRAF - Canada scraps Boeing deal, talks tough on upcoming contract for 88 jets https://seekingalpha.com/news/3317836-canada-scraps-boeing-deal-talks-tough-on-upcoming-contract-for-88-jets?source=tweet\" data-url=\"https://seekingalpha.com/news/3317836-canada-scraps-boeing-deal-talks-tough-on-upcoming-contract-for-88-jets\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:14 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>102&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317832\" data-ts=\"1513108565\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317832-technology-top-gainers-losers-of-2-55-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top Gainers / Losers as of 2:55 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/PTI' title='Proteostasis Therapeutics'>PTI</a> <font color='green'>+153%</font>. <a href='https://seekingalpha.com/symbol/TCCO' title='Technical Communications Corp.'>TCCO</a> <font color='green'>+21%</font>. <a href='https://seekingalpha.com/symbol/DPW' title='DPW Holdings, Inc.'>DPW</a> <font color='green'>+20%</font>. <a href='https://seekingalpha.com/symbol/ELTK' title='Eltek Ltd.'>ELTK</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/BSQR' title='BSQUARE Corporation'>BSQR</a> <font color='green'>+14%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/RSYS' title='RadiSys Corporation'>RSYS</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/MARK' title='Remark Holdings, Inc.'>MARK</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/CRCM' title='Care.com, Inc.'>CRCM</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/SIFY' title='Sify Technologies Limited'>SIFY</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/IOTS' title='Adesto Technologies'>IOTS</a> <font color='red'>-8%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3317832\" data-linked=\"Technology - Top Gainers / Losers as of 2:55 pm\" data-tweet=\"$PTI $TCCO $DPW - Technology - Top Gainers / Losers as of 2:55 pm https://seekingalpha.com/news/3317832-technology-top-gainers-losers-of-2-55-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3317832-technology-top-gainers-losers-of-2-55-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:56 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317831\" data-ts=\"1513108083\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OAS\" target=\"_blank\">OAS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317831-oasis-petroleumminus-15-after-paying-hefty-price-for-delaware-basin-acres\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Oasis Petroleum -15% after paying &#39;hefty price&#39; for Delaware Basin acres</a></h4><ul>     <li>Oasis Petroleum (<a href='https://seekingalpha.com/symbol/OAS' title='Oasis Petroleum Inc.'>OAS</a> <font color='red'>-14.7%</font>) plunges ~15%, most on the NYSE, in heavy volume as investors show their dismay over the company's planned <a href=\"https://seekingalpha.com/news/3317605-oasis-petroleum-buys-20k-delaware-basin-acres-946m\" target=\"_blank\">public offering of 32M common shares</a>.</li><li>OAS agreed to buy 20.3K acres in the Delaware Basin for $946M, consisting of $483M in cash and 46M common shares of common stock, meaning the company is issuing 78M new shares - substantial dilution to existing investors  considering it had ~233M shares outstanding as of  the end of Q3.</li><li>The deal also is viewed as a departure from its Bakken-focused strategy, and its per acre price of $46,660 <a href=\"https://www.fool.com/investing/2017/12/12/heres-why-investors-are-punishing-oasis-petroleum.aspx\" target=\"_blank\">looks like a hefty premium</a>; Motley Fool's Matthew DiLallo notes two deals in the same region by Marathon Oil in March, one in which MRO paid $1.1B for  70K net acres (~$15K/acre) and the second&nbsp; in which it spent $700M for 21K net acres (~$33,333/acre).</li><li>SunTrust Robinson Humphrey <a href=\"https://www.streetinsider.com/Analyst+Comments/SunTrust+Robinson+Humphrey+Downgrades+Oasis+Petroleum+%28OAS%29+to+Hold+Following+Land+Acquisition/13591374.html\" target=\"_blank\">downgrades</a> shares to Hold from Buy with an $11 price target, cut from $14, citing the \"hefty price\" OAS paid to enter the Delaware Basin.</li></ul><div class=\"tiny-share-widget\" data-id=\"3317831\" data-linked=\"Oasis Petroleum -15% after paying &#39;hefty price&#39; for Delaware Basin acres\" data-tweet=\"$OAS - Oasis Petroleum -15% after paying &#39;hefty price&#39; for Delaware Basin acres https://seekingalpha.com/news/3317831-oasis-petroleumminus-15-after-paying-hefty-price-for-delaware-basin-acres?source=tweet\" data-url=\"https://seekingalpha.com/news/3317831-oasis-petroleumminus-15-after-paying-hefty-price-for-delaware-basin-acres\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:48 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317822\" data-ts=\"1513105954\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EDIT\" target=\"_blank\">EDIT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317822-crispr-cas9-gene-editing-players-sell-off-down-much-4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CRISPR/Cas9 gene editing players sell off, down as much as 4%</a></h4><ul><li>CRISPR/Cas9 gene editing outfits Editas Medicine (<a href='https://seekingalpha.com/symbol/EDIT' title='Editas Medicine'>EDIT</a> <font color='red'>-2.2%</font>), Intellia Therapeutics (<a href='https://seekingalpha.com/symbol/NTLA' title='Intellia Therapeutics'>NTLA</a> <font color='red'>-2%</font>) and CRISPR Therapeutics (<a href='https://seekingalpha.com/symbol/CRSP' title='CRISPR Therapeutics'>CRSP</a> <font color='red'>-3.6%</font>) are all under pressure mid-session.</li><li>The culprit appears to be an <a href=\"https://eurekalert.org/pub_releases/2017-12/bch-pig121117.php\" target=\"_blank\">article </a>from EurekAlert!, published by the American Association for the Advancement of Science, citing a study implying that people's unique genetic differences could undermine the efficacy of CRISPR/Cas9, regarded by many as the \"next big thing\" in biotech. Such differences could mean than the gene edited therapy will need to be customized to each patient's genome.</li><li>The study, led by Boston Children's Hospital and the University of Montreal, analyzed 7,444 previously published whole-genome sequences to determine if any of the individuals carried DNA sequence variants in the areas targeted by the guide RNAs used to direct CRISPR/Cas9 enzymes to the desired DNA locations for ~30 high-priority diseases. Results revealed that about 50% of analyzed guide RNAs could be potentially affected by such variants. In a few cases, the genetic variants could cause off-target editing which, in rare cases, could have serious consequences.</li><li>The data will appear this week in the <em>Proceedings of the National Academy of Sciences Early Edition</em>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3317822\" data-linked=\"CRISPR/Cas9 gene editing players sell off, down as much as 4%\" data-tweet=\"$EDIT $EDIT $NTLA - CRISPR/Cas9 gene editing players sell off, down as much as 4% https://seekingalpha.com/news/3317822-crispr-cas9-gene-editing-players-sell-off-down-much-4?source=tweet\" data-url=\"https://seekingalpha.com/news/3317822-crispr-cas9-gene-editing-players-sell-off-down-much-4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:12 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>18&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317824\" data-ts=\"1513105448\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317824-energy-materials-top-gainers-losers-of-2-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials - Top Gainers / Losers as of 2:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/KMG' title='KMG Chemicals, Inc.'>KMG</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/HOS' title='Hornbeck Offshore Services, Inc.'>HOS</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/KEG' title='Key Energy Services, Inc.'>KEG</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/EPE' title='EP Energy Corporation'>EPE</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/PUMP' title='ProPetro'>PUMP</a> <font color='green'>+6%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/YTEN' title='Yield10 Bioscience, Inc.'>YTEN</a> <font color='red'>-24%</font>. <a href='https://seekingalpha.com/symbol/OAS' title='Oasis Petroleum Inc.'>OAS</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/KOS' title='Kosmos Energy'>KOS</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/PGLC' title='Pershing Gold Corporation'>PGLC</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/ERN' title='Erin Energy Corp.'>ERN</a> <font color='red'>-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3317824\" data-linked=\"Energy/Materials - Top Gainers / Losers as of 2:00 pm\" data-tweet=\"$KMG $HOS $KEG - Energy/Materials - Top Gainers / Losers as of 2:00 pm https://seekingalpha.com/news/3317824-energy-materials-top-gainers-losers-of-2-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3317824-energy-materials-top-gainers-losers-of-2-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:04 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317819\" data-ts=\"1513103733\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EYES\" target=\"_blank\">EYES</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317819-second-sight-continues-rally-up-21\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Second Sight continues rally, up 21%</a></h4><ul><li>Micro cap Second Sight Medical (<a href='https://seekingalpha.com/symbol/EYES' title='Second Sight Medical Products'>EYES</a> <font color='green'>+20.5%</font>) adds to its December rally on triple normal volume. Shares have more than doubled from the December 1 low of $1.16.</li><li>On December 5, the company <a href=\"https://seekingalpha.com/pr/17018532-second-sight-announces-market-entry-iran-first-two-implants-argus-ii-retinal-prosthesis\" target=\"_blank\">announced </a>the entry of Argus II in Iran. Two implants were recently performed there, facilitated by distribution partner Arshia Gostar Darman.</li></ul><div class=\"tiny-share-widget\" data-id=\"3317819\" data-linked=\"Second Sight continues rally, up 21%\" data-tweet=\"$EYES - Second Sight continues rally, up 21% https://seekingalpha.com/news/3317819-second-sight-continues-rally-up-21?source=tweet\" data-url=\"https://seekingalpha.com/news/3317819-second-sight-continues-rally-up-21\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:35 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>16&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317801\" data-ts=\"1513101018\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SLNO\" target=\"_blank\">SLNO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317801-soleno-therapeutics-secures-private-15m-capital-raise-shares-up-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Soleno Therapeutics secures private $15M capital raise; shares up 2%</a></h4><ul><li>Soleno Therapeutics (<a href='https://seekingalpha.com/symbol/SLNO' title='Soleno Therapeutics, Inc.'>SLNO</a> <font color='green'>+2.3%</font>) inks an <a href=\"https://seekingalpha.com/pr/17024480-soleno-therapeutics-announces-15-million-private-placement\" target=\"_blank\">agreement </a>with certain investors for the direct sale of 8,141,116 shares of common stock at $1.8425 per share yielding ~$15M in proceeds.</li><li>Each share sold will be issued with a three-year warrant to purchase 0.74 of a share of common at $2.00 per share. In the event of positive late-stage results for diazoxide choline controlled-release tablet &#40;DCCR&#41; in Prader-Willi syndrome, the warrants will expire 30 days from the company's announcement of the outcome.</li><li>Proceeds will fund the Phase 3 study which should launch next quarter.</li><li><a href=\"https://soleno.life/dccr/\" target=\"_blank\">DCCR </a>is a crystalline salt of diazoxide, a potassium channel activator (a vasodilator) which causes smooth muscle to relax by increasing membrane permeability to potassium ions. Teva Pharmaceutical Industries markets diazoxide free base under the brand name <a href=\"https://www.rxlist.com/proglycem-drug.htm\" target=\"_blank\">PROGLYCEM </a>for the treatment of low blood sugar.</li><li><a href=\"https://ghr.nlm.nih.gov/condition/prader-willi-syndrome\" target=\"_blank\">Prader-Willi syndrome</a> is an inherited disorder characterized by weak muscle tone, feeding difficulties, delayed development and poor growth. Affected people develop an insatiable appetite that leads to obesity.</li></ul><div class=\"tiny-share-widget\" data-id=\"3317801\" data-linked=\"Soleno Therapeutics secures private $15M capital raise; shares up 2%\" data-tweet=\"$SLNO - Soleno Therapeutics secures private $15M capital raise; shares up 2% https://seekingalpha.com/news/3317801-soleno-therapeutics-secures-private-15m-capital-raise-shares-up-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3317801-soleno-therapeutics-secures-private-15m-capital-raise-shares-up-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:50 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317802\" data-ts=\"1513100440\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317802-midday-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/PTI' title='Proteostasis Therapeutics'>PTI</a> <font color='green'>+161%</font>. <a href='https://seekingalpha.com/symbol/TIK' title='Tel-Instrument Electronics Corp'>TIK</a> <font color='green'>+46%</font>. <a href='https://seekingalpha.com/symbol/RIOT' title='Riot Blockchain, Inc.'>RIOT</a> <font color='green'>+33%</font>. <a href='https://seekingalpha.com/symbol/GLYC' title='GlycoMimetics'>GLYC</a> <font color='green'>+25%</font>. <a href='https://seekingalpha.com/symbol/ELTK' title='Eltek Ltd.'>ELTK</a> <font color='green'>+24%</font>. <a href='https://seekingalpha.com/symbol/DPW' title='DPW Holdings, Inc.'>DPW</a> <font color='green'>+21%</font>. <a href='https://seekingalpha.com/symbol/PYDS' title='Payment Data Systems, Inc.'>PYDS</a> <font color='green'>+20%</font>. <a href='https://seekingalpha.com/symbol/TCCO' title='Technical Communications Corp.'>TCCO</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/SRI' title='Stoneridge, Inc.'>SRI</a> <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/BSQR' title='BSQUARE Corporation'>BSQR</a> <font color='green'>+18%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/YTEN' title='Yield10 Bioscience, Inc.'>YTEN</a> <font color='red'>-24%</font>. PPHM <font color='red'>-20%</font>. <a href='https://seekingalpha.com/symbol/CASI' title='CASI Pharmaceuticals'>CASI</a> <font color='red'>-16%</font>. <a href='https://seekingalpha.com/symbol/ACER' title='Acer Therapeutics Inc.'>ACER</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/OAS' title='Oasis Petroleum Inc.'>OAS</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/GLBS' title='Globus Maritime Ltd.'>GLBS</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/KOS' title='Kosmos Energy'>KOS</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/NCS' title='NCI Building Systems Inc.'>NCS</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/RSYS' title='RadiSys Corporation'>RSYS</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/GBT' title='Global Blood Therapeutics'>GBT</a> <font color='red'>-10%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3317802\" data-linked=\"Midday Gainers / Losers\" data-tweet=\"$PTI $TIK $RIOT - Midday Gainers / Losers https://seekingalpha.com/news/3317802-midday-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3317802-midday-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:40 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317800\" data-ts=\"1513100315\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VZ\" target=\"_blank\">VZ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317800-verizonplus-2_4-nomura-upgrades-to-buy-sees-15-plus-upside\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Verizon +2.4% as Nomura upgrades to Buy, sees 15%-plus upside</a></h4><ul>    <li>Verizon (NYSE:<a href='https://seekingalpha.com/symbol/VZ' title='Verizon Communications'>VZ</a>) is <font color='green'>up 2.4%</font> and inching close to its 52-week high (set in the first few trading days of 2017) after an upgrade to Buy at Nomura Instinet.</li>    <li>Jeffrey Kvaal had previously rated the stock Neutral, as have about two dozen other analysts.</li>    <li>But he's joining 10 others in the Buy column, and boosted his price target on the stock to $61 from $47, implying about 15% upside from today's higher price.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3317800\" data-linked=\"Verizon +2.4% as Nomura upgrades to Buy, sees 15%-plus upside\" data-tweet=\"$VZ - Verizon +2.4% as Nomura upgrades to Buy, sees 15%-plus upside https://seekingalpha.com/news/3317800-verizonplus-2_4-nomura-upgrades-to-buy-sees-15-plus-upside?source=tweet\" data-url=\"https://seekingalpha.com/news/3317800-verizonplus-2_4-nomura-upgrades-to-buy-sees-15-plus-upside\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:38 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317798\" data-ts=\"1513099843\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MU\" target=\"_blank\">MU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317798-nanya-sells-micron-shares\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nanya sells Micron shares</a></h4><ul><li>        Nanya Technology <a href=\"https://www.reuters.com/article/brief-nanya-technology-sells-microns-sha/brief-nanya-technology-sells-microns-shares-for-22-4-mln-idUSH9N1O801T?feedType=RSS&amp;feedName=companyNews&amp;utm_source=feedburner&amp;utm_medium=feed&amp;utm_campaign=Feed%3A+reuters%2FcompanyNews+%28News+%2F+US+%2F+Company+News%29\" target=\"_blank\">announces</a> selling Micron (NASDAQ:<a href='https://seekingalpha.com/symbol/MU' title='Micron Technology Inc.'>MU</a>) shares for $22.4M.</li><li>               Nanya expects net income of $13.4M from the transaction.&nbsp;</li><li>                  Micron shares are&nbsp;<font color='red'>down 1.2%</font>. &nbsp; </li><li>Previously: <a href=\"https://seekingalpha.com/news/3316573-micron-suing-umc-trade-secret-infringement\" target=\"_blank\">Micron suing UMC for trade secret infringement</a> (Dec. 6)</li></ul><div class=\"tiny-share-widget\" data-id=\"3317798\" data-linked=\"Nanya sells Micron shares\" data-tweet=\"$MU - Nanya sells Micron shares https://seekingalpha.com/news/3317798-nanya-sells-micron-shares?source=tweet\" data-url=\"https://seekingalpha.com/news/3317798-nanya-sells-micron-shares\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:30 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>100&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317796\" data-ts=\"1513099599\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CMTA\" target=\"_blank\">CMTA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317796-clementia-pharma-launches-late-stage-study-of-palovarotene-in-rare-extra-skeletal-bone\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Clementia Pharma launches late-stage study of palovarotene in rare extra-skeletal bone disorder; shares up 2%</a></h4><ul><li>Relatively recent IPO&nbsp;Clementia Pharmaceuticals (<a href='https://seekingalpha.com/symbol/CMTA' title='Clementia Pharmaceuticals'>CMTA</a> <font color='green'>+2.2%</font>) <a href=\"https://seekingalpha.com/pr/17024121-clementia-initiates-pivotal-phase-3-move-trial-palovarotene-patients-fibrodysplasia\" target=\"_blank\">commences </a>a Phase 3 clinical trial assessing lead candidate palovarotene in patients with <a href=\"https://ghr.nlm.nih.gov/condition/fibrodysplasia-ossificans-progressiva#statistics\" target=\"_blank\">fibrodysplasia ossificans progressiva </a>&#40;FOP&#41;, a rare genetic disorder in which muscle and connective tissue are gradually replaced by bone.</li><li>The study, <a href=\"https://clinicaltrials.gov/ct2/show/NCT03312634?spons=clementia&amp;rank=1\" target=\"_blank\">MOVE</a>, will evaluate a single daily dose of paloverotene which will be increased during flare-ups. The primary endpoint is the annualized change in new heterotopic ossification (presence of bone in soft tissue) volume, screened every six months for up to two years.</li><li>Topline data should be available in late 2020. The first interim data readout should happen in early 2019.</li><li><a href=\"http://clementiapharma.com/our-pipeline/palovarotene/\" target=\"_blank\">Palovarotene</a>, licensed from Roche, is a small molecule retinoic acid receptor gamma agonist. In mouse models, it inhibited the formation of bone tumors called <a href=\"https://en.wikipedia.org/wiki/Osteochondroma\" target=\"_blank\">osteochondromas</a>, cartilage-capped bony projections on the surface of bones.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3283704-clementia-pharmaceuticals-deck-ipo\" target=\"_blank\">Clementia Pharmaceuticals on deck for IPO</a> (Aug. 1)</li></ul><div class=\"tiny-share-widget\" data-id=\"3317796\" data-linked=\"Clementia Pharma launches late-stage study of palovarotene in rare extra-skeletal bone disorder; shares up 2%\" data-tweet=\"$CMTA - Clementia Pharma launches late-stage study of palovarotene in rare extra-skeletal bone disorder; shares up 2% https://seekingalpha.com/news/3317796-clementia-pharma-launches-late-stage-study-of-palovarotene-in-rare-extra-skeletal-bone?source=tweet\" data-url=\"https://seekingalpha.com/news/3317796-clementia-pharma-launches-late-stage-study-of-palovarotene-in-rare-extra-skeletal-bone\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:26 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317797\" data-ts=\"1513099532\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BOX\" target=\"_blank\">BOX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317797-box-launches-new-consulting-service\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Box launches new consulting service</a></h4><ul><li>        Box (NYSE:<a href='https://seekingalpha.com/symbol/BOX' title='Box'>BOX</a>) <a href=\"https://seekingalpha.com/pr/17024992-box-launches-box-transform-consulting-service-drive-digital-transformation-enterprises\" target=\"_blank\">announces</a> Box Transform, a program offering customers a dedicated Box consultant to help implement advanced cloud content. &nbsp;</li><li>        The service provides Box technology and a helper to best utilize and deploy that technology.</li><li>               Box Transform is part of Box Consulting and is now available for customers.&nbsp;</li><li>               Box shares are<font color='green'>&nbsp;up 1.4%</font>.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3317797\" data-linked=\"Box launches new consulting service\" data-tweet=\"$BOX - Box launches new consulting service https://seekingalpha.com/news/3317797-box-launches-new-consulting-service?source=tweet\" data-url=\"https://seekingalpha.com/news/3317797-box-launches-new-consulting-service\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:25 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317795\" data-ts=\"1513099126\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NTR\" target=\"_blank\">NTR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317795-agrium-to-buy-louis-dreyfus-fertilizer-business-in-australia\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Agrium to buy Louis Dreyfus fertilizer business in Australia</a></h4><ul>     <li>Agrium (AGU <font color='green'>+3%</font>) moves higher after <a href=\"https://seekingalpha.com/pr/17024931-agrium-acquire-louis-dreyfus-companys-fertilizer-business-australia\" target=\"_blank\">agreeing to acquire</a> the Australian fertilizer business of commodities trader Louis Dreyfus for an undisclosed sum.</li>     <li>Macrofertil's Austrlaian network includes six fertilizer storage and distribution assets with coating and blending capabilities, and has annual volumes of more than 300K metric tons with $120M/year in sales.</li>     <li>AGU says the acquisition will complement its existing network of ~400 sites in Australia.</li></ul><div class=\"tiny-share-widget\" data-id=\"3317795\" data-linked=\"Agrium to buy Louis Dreyfus fertilizer business in Australia\" data-tweet=\"$NTR - Agrium to buy Louis Dreyfus fertilizer business in Australia https://seekingalpha.com/news/3317795-agrium-to-buy-louis-dreyfus-fertilizer-business-in-australia?source=tweet\" data-url=\"https://seekingalpha.com/news/3317795-agrium-to-buy-louis-dreyfus-fertilizer-business-in-australia\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:18 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317793\" data-ts=\"1513098135\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317793-consumer-top-gainers-losers-of-12-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top Gainers / Losers as of 12:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/SRI' title='Stoneridge, Inc.'>SRI</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/KBSF' title='KBS Fashion Group Limited'>KBSF</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/AVP' title='Avon Products, Inc.'>AVP</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/IRBT' title='iRobot Corporation'>IRBT</a> <font color='green'>+6%</font>. LTEA <font color='green'>+6%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/RELV' title='Reliv&#39; International, Inc.'>RELV</a> <font color='red'>-8%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3317793\" data-linked=\"Consumer - Top Gainers / Losers as of 12:00 pm\" data-tweet=\"$SRI $KBSF $AVP - Consumer - Top Gainers / Losers as of 12:00 pm https://seekingalpha.com/news/3317793-consumer-top-gainers-losers-of-12-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3317793-consumer-top-gainers-losers-of-12-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:02 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317792\" data-ts=\"1513097923\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GENE\" target=\"_blank\">GENE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317792-genetic-tech-up-11-on-takeover-interest\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Genetic Tech up 11% on takeover interest</a></h4><ul><li>Thinly traded nano cap Genetic Technologies (<a href='https://seekingalpha.com/symbol/GENE' title='GENETIC TECHNOLOGIES LTD'>GENE</a> <font color='green'>+10.7%</font>) is up more than double normal volume after it <a href=\"https://seekingalpha.com/pr/17024047-genetic-technologies-provides-update-strategic-review-initiative\" target=\"_blank\">announced </a>that potential suitors made presentations to the Chairman and CEO in late November.</li><li>In August, it announced that it had initiated a review of strategic alternatives, including an outright sale of the company.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3291763-genetic-technologies-announces-comprehensive-review-strategic-alternatives\" target=\"_blank\">Genetic Technologies announces comprehensive review of strategic alternatives</a> (Aug. 25)</li></ul><div class=\"tiny-share-widget\" data-id=\"3317792\" data-linked=\"Genetic Tech up 11% on takeover interest\" data-tweet=\"$GENE - Genetic Tech up 11% on takeover interest https://seekingalpha.com/news/3317792-genetic-tech-up-11-on-takeover-interest?source=tweet\" data-url=\"https://seekingalpha.com/news/3317792-genetic-tech-up-11-on-takeover-interest\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:58 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317789\" data-ts=\"1513097373\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MCHX\" target=\"_blank\">MCHX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317789-marchexplus-1_6-after-0_50-share-special-dividend\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Marchex +1.6% after $0.50/share special dividend</a></h4><ul>   <li>Marchex (NASDAQ:<a href='https://seekingalpha.com/symbol/MCHX' title='Marchex, Inc.'>MCHX</a>) is <font color='green'>up 1.6%</font> after <a href=\"https://seekingalpha.com/news/3317738-marchex-declares-0_50-dividend\" target=\"_blank\">declaring a special dividend</a> of $0.50/share.</li>    <li>The company's been undergoing a strategic review, but CFO Michael Arends says &ldquo;We&rsquo;ve made significant strides over the last year in stabilizing our business.\"</li>    <li>\"While there is more to do, we are focused on unlocking the opportunities for value creation within the call and speech analytics industry,&rdquo; he adds. &ldquo;Given the strength of our balance sheet, we believe we can issue this dividend while continuing to retain the flexibility to pursue new opportunities.\"</li> </ul><div class=\"tiny-share-widget\" data-id=\"3317789\" data-linked=\"Marchex +1.6% after $0.50/share special dividend\" data-tweet=\"$MCHX - Marchex +1.6% after $0.50/share special dividend https://seekingalpha.com/news/3317789-marchexplus-1_6-after-0_50-share-special-dividend?source=tweet\" data-url=\"https://seekingalpha.com/news/3317789-marchexplus-1_6-after-0_50-share-special-dividend\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:49 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317784\" data-ts=\"1513097206\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CYCC\" target=\"_blank\">CYCC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317784-cyclacel-optimistic-subgroup-of-patients-in-failed-late-stage-study-of-sapacitabine-investors\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cyclacel optimistic with subgroup of patients in failed late-stage study of sapacitabine; investors not on board, shares down 7%</a></h4><ul><li>Cyclacel Pharmaceuticals (<a href='https://seekingalpha.com/symbol/CYCC' title='Cyclacel Pharmaceuticals, Inc.'>CYCC</a> <font color='red'>-7.3%</font>) slumps on almost double normal volume on the heels of the <a href=\"https://seekingalpha.com/pr/17024168-cyclacel-announces-presentation-results-phase-3-seamless-study-ash-annual-meeting\" target=\"_blank\">release </a>of final results from a Phase 3 clinical trial, SEAMLESS, assessing lead candidate sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia &#40;AML&#41;. The data were presented at ASH in Atlanta.</li><li>Investors are apparently disappointed that there was not more of an opportunity with a subset of patients in the failed study, first announced in February.</li><li>SEAMLESS did not achieve the primary endpoint of a statistically significant improvement overall survival &#40;OS&#41; in the sapacitabine + decitabine arm compared to decitabine alone, although the rate of complete remission favored the sapacitabine group, 17% versus 11%.</li><li>In a subgroup of AML patients with white blood cell &#40;WBC&#41;&nbsp;counts less than 10K, median OS favored sapacitabine, 8.0 months versus 5.8 months. In patients with WBC counts at least 10K, OS was statistically significantly better in the decitabine arm (5.5 months versus 3.8 months; p=0.007).</li><li><a href=\"http://www.cyclacel.com/research_programs_oncology_cyc682.shtml\" target=\"_blank\">Sapacitabine</a>&nbsp;is an oral nucleoside analogue prodrug whose metabolite, CNDAC, arrests the cell cycle by breaking up DNA.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3245739-cyclacels-lead-product-candidate-flunks-late-stage-leukemia-study-shares-19-percent-premarket\" target=\"_blank\">Cyclacel's lead product candidate flunks late-stage leukemia study; shares down 19% premarket</a> (Feb. 23)</li></ul><div class=\"tiny-share-widget\" data-id=\"3317784\" data-linked=\"Cyclacel optimistic with subgroup of patients in failed late-stage study of sapacitabine; investors not on board, shares down 7%\" data-tweet=\"$CYCC - Cyclacel optimistic with subgroup of patients in failed late-stage study of sapacitabine; investors not on board, shares down 7% https://seekingalpha.com/news/3317784-cyclacel-optimistic-subgroup-of-patients-in-failed-late-stage-study-of-sapacitabine-investors?source=tweet\" data-url=\"https://seekingalpha.com/news/3317784-cyclacel-optimistic-subgroup-of-patients-in-failed-late-stage-study-of-sapacitabine-investors\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:46 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317788\" data-ts=\"1513097169\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ZAYO\" target=\"_blank\">ZAYO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317788-morgan-stanley-upgrades-zayo-group\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Morgan Stanley upgrades Zayo Group</a></h4><ul><li>        Morgan Stanley <a href=\"https://www.benzinga.com/analyst-ratings/analyst-color/17/12/10902553/2-reasons-morgan-stanley-upgraded-zayo-group\" target=\"_blank\">upgrades</a> Zayo Group Holdings (NYSE:<a href='https://seekingalpha.com/symbol/ZAYO' title='Zayo Group'>ZAYO</a>) to Overweight from Equal Weight and raises the price target from $33 to $40.</li><li>               Analyst Simon Flannery cites the upcoming REIT conversion and Zayo&rsquo;s improving revenue.&nbsp;</li><li>               Flannery expects the company&rsquo;s recent churn to moderate and help net adds.&nbsp;</li><li>                  Zayo shares are&nbsp;<font color='green'>up 3.9%</font>.&nbsp; &nbsp;&nbsp;   &nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3317788\" data-linked=\"Morgan Stanley upgrades Zayo Group\" data-tweet=\"$ZAYO - Morgan Stanley upgrades Zayo Group https://seekingalpha.com/news/3317788-morgan-stanley-upgrades-zayo-group?source=tweet\" data-url=\"https://seekingalpha.com/news/3317788-morgan-stanley-upgrades-zayo-group\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:46 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317783\" data-ts=\"1513095150\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FATE\" target=\"_blank\">FATE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317783-fate-therapeutics-protmune-shows-positive-effect-in-early-stage-study-shares-up-5\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fate Therapeutics&#39; ProTmune shows positive effect in early-stage study; shares up 5%</a></h4><ul><li>Fate Therapeutics (<a href='https://seekingalpha.com/symbol/FATE' title='Fate Therapeutics, Inc.'>FATE</a> <font color='green'>+4.6%</font>) is up in early trading on average volume on the heels of its <a href=\"https://seekingalpha.com/pr/17023925-fate-therapeutics-announces-day-100-clinical-results-phase-1-stage-protect-trial-protmune\" target=\"_blank\">announcement </a>of positive interim data from the first phase of its Phase 1/2 clinical trial, PROTECT, assessing ProTmune in patients with blood cancers. The results were presented at ASH in Atlanta.</li><li>During the first 100 days after seven patients received hematopoietic cell transplants &#40;HCT&#41;, all were alive and relapse-free. Three of the seven developed acute graft-versus-host disease (GvHD) but all responded to standard-of-care steroid treatment with a median time to resolution of the maximum GvHD grade of seven days (range: 5-8 days).</li><li>All subjects receiving ProTmune in Phase 1 will be followed for two years post-HCT.</li><li>Phase 2 of <a href=\"https://clinicaltrials.gov/ct2/show/NCT02743351?spons=fate+therapeutics&amp;rank=2\" target=\"_blank\">PROTECT </a>will randomize up to 60 subjects to assess the safety and efficacy of ProTmune versus placebo. Participants will be adults with blood cancers undergoing matched unrelated donor HCT following myeloablative conditioning (use of chemo or radiation to destroy hematopoietic stem white blood cells prior to HCT). The primary endpoint is the incidence of Grades 2-4 GvHD within 100 days of HCT.</li><li><a href=\"http://fatetherapeutics.com/product-pipeline/immuno-protection-franchise/protmune/\" target=\"_blank\">ProTmune&nbsp;</a>is a programmed cellular immunotherapy that is designed for use as an allogeneic hematopoietic cell source for HCT. It is produced by modulating mobilized peripheral blood with two small molecules to enhance the biological properties and therapeutic function of immune cells.</li></ul><div class=\"tiny-share-widget\" data-id=\"3317783\" data-linked=\"Fate Therapeutics&#39; ProTmune shows positive effect in early-stage study; shares up 5%\" data-tweet=\"$FATE - Fate Therapeutics&#39; ProTmune shows positive effect in early-stage study; shares up 5% https://seekingalpha.com/news/3317783-fate-therapeutics-protmune-shows-positive-effect-in-early-stage-study-shares-up-5?source=tweet\" data-url=\"https://seekingalpha.com/news/3317783-fate-therapeutics-protmune-shows-positive-effect-in-early-stage-study-shares-up-5\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:12 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317782\" data-ts=\"1513095097\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NAV\" target=\"_blank\">NAV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317782-navistar-rallies-after-stifel-conviction\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Navistar rallies after Stifel conviction</a></h4><ul> <li>A big shot in the arm for Navistar (<a href='https://seekingalpha.com/symbol/NAV' title='Navistar International Corporation'>NAV</a> <font color='green'>+4.3%</font>) arrives with a bullish note from Stifel Nicolaus.</li> <li>The firm points to improving trends in the truck market and the upside of the new 12.4L A26 engine.</li> <li>The investment by Volkswagen in Navistar is also seen as a near-term positive.</li> <li>Stifel rates Navistar at Buy and issues a price target raise to $50. On a longer view, the firm sees Navistar's share price running to as high as $75.</li><li>Sources: CNBC and Bloomberg</li> </ul><div class=\"tiny-share-widget\" data-id=\"3317782\" data-linked=\"Navistar rallies after Stifel conviction\" data-tweet=\"$NAV - Navistar rallies after Stifel conviction https://seekingalpha.com/news/3317782-navistar-rallies-after-stifel-conviction?source=tweet\" data-url=\"https://seekingalpha.com/news/3317782-navistar-rallies-after-stifel-conviction\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:11 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317759\" data-ts=\"1513094496\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317759-healthcare-top-5-gainers-losers-of-11-00\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers as of 11:00 am</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/RIOT' title='Riot Blockchain, Inc.'>RIOT</a> <font color='green'>+33%</font>. <a href='https://seekingalpha.com/symbol/GLYC' title='GlycoMimetics'>GLYC</a> <font color='green'>+24%</font>. <a href='https://seekingalpha.com/symbol/NEPT' title='Neptune Wellness Solutions Inc.'>NEPT</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/ATNX' title='Athenex, Inc.'>ATNX</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/EYES' title='Second Sight Medical Products'>EYES</a> <font color='green'>+10%</font>.</li><li><b>Losers:</b> PPHM <font color='red'>-21%</font>. <a href='https://seekingalpha.com/symbol/ACER' title='Acer Therapeutics Inc.'>ACER</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/CASI' title='CASI Pharmaceuticals'>CASI</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/AKTX' title='Akari Therapeutics Plc'>AKTX</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/CYCC' title='Cyclacel Pharmaceuticals, Inc.'>CYCC</a> <font color='red'>-10%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3317759\" data-linked=\"Healthcare - Top 5 Gainers / Losers as of 11:00 am\" data-tweet=\"$RIOT $GLYC $NEPT - Healthcare - Top 5 Gainers / Losers as of 11:00 am https://seekingalpha.com/news/3317759-healthcare-top-5-gainers-losers-of-11-00?source=tweet\" data-url=\"https://seekingalpha.com/news/3317759-healthcare-top-5-gainers-losers-of-11-00\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:01 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317778\" data-ts=\"1513093966\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VHC\" target=\"_blank\">VHC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317778-asgard-managed-services-and-virnetx-announce-provider-agreement\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Asgard Managed Services and VirnetX announce provider agreement</a></h4><ul><li>        Asgard Managed Services and VirnetX (NYSEMKT:<a href='https://seekingalpha.com/symbol/VHC' title='VirnetX Holding Corporation'>VHC</a>) <a href=\"https://seekingalpha.com/pr/17024737-asgard-signs-virnetx-sell-gabriel-encrypted-communications-secure-domain-names\" target=\"_blank\">announce</a> a non-exclusive provider agreement for Asgard to sell VirnetX&rsquo;s Gabriel Collaboration Suite and offer VirnetX&rsquo;s Secure Domain Name tech.</li><li>                  No financial details available.    </li><li>               VirnetX shares are&nbsp;<font color='green'>up 2.6%</font>. &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3302236-virnetx-drops-preliminary-q3-results\" target=\"_blank\">VirnetX drops after preliminary Q3 results</a> (Oct. 19)</li></ul><div class=\"tiny-share-widget\" data-id=\"3317778\" data-linked=\"Asgard Managed Services and VirnetX announce provider agreement\" data-tweet=\"$VHC - Asgard Managed Services and VirnetX announce provider agreement https://seekingalpha.com/news/3317778-asgard-managed-services-and-virnetx-announce-provider-agreement?source=tweet\" data-url=\"https://seekingalpha.com/news/3317778-asgard-managed-services-and-virnetx-announce-provider-agreement\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:52 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317775\" data-ts=\"1513093393\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GSK\" target=\"_blank\">GSK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317775-fda-oks-expanded-use-for-glaxos-nucala-shares-up-1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA OKs expanded use for Glaxo&#39;s Nucala; shares up 1%</a></h4><ul><li>The FDA <a href=\"https://www.prnewswire.com/news-releases/fda-approves-first-drug-for-eosinophilic-granulomatosis-with-polyangiitis-a-rare-disease-formerly-known-as-the-churg-strauss-syndrome-300570130.html\" target=\"_blank\">approves </a>the use of GlaxoSmithKline's (<a href='https://seekingalpha.com/symbol/GSK' title='GlaxoSmithKline'>GSK</a> <font color='green'>+0.6%</font>) Nucala (mepolizumab) to treat adult patients with eosinophilic granulomatosis with polyangiitis, a rare autoimmune disorder that causes blood vessel inflammation.</li><li><a href=\"https://www.nucala.com/\" target=\"_blank\">Nucala </a>was first approved in the U.S. in 2015 for eosinophilic asthma.</li></ul><div class=\"tiny-share-widget\" data-id=\"3317775\" data-linked=\"FDA OKs expanded use for Glaxo&#39;s Nucala; shares up 1%\" data-tweet=\"$GSK - FDA OKs expanded use for Glaxo&#39;s Nucala; shares up 1% https://seekingalpha.com/news/3317775-fda-oks-expanded-use-for-glaxos-nucala-shares-up-1?source=tweet\" data-url=\"https://seekingalpha.com/news/3317775-fda-oks-expanded-use-for-glaxos-nucala-shares-up-1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:43 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317770\" data-ts=\"1513092180\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EIX\" target=\"_blank\">EIX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317770-edison-says-fire-investigations-now-include-possible-role-of-facilities\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Edison says fire investigations now include possible role of its facilities</a></h4><ul>     <li>Edison International (<a href='https://seekingalpha.com/symbol/EIX' title='Edison International'>EIX</a> <font color='red'>-7%</font>) sinks in early trading following an <a href=\"https://seekingalpha.com/pr/17023909-southern-california-edison-responds-area-fires\" target=\"_blank\">investor update</a> on the wind-driven Southern California wildfires that are affecting customers and  electric service in Southern California Edison's service territory.</li>     <li>The causes of the wildfires are being investigated by fire protection agency CAL FIRE, other fire agencies and the California Public Utilities Commission, but SoCal Edison believes the investigations now include locations beyond those identified last week as the apparent origin of the fires as well as the possible role of its facilities.</li>     <li>The fires have <a href=\"http://fox61.com/2017/12/12/california-wildfires-have-destroyed-1000-structures-and-counting/\" target=\"_blank\">destroyed more than 1,000 structures</a> since igniting last week; the Thomas Fire - one of six in total - is larger than all of New York City and was ~20% contained as of last night, according to CAL FIRE.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3317770\" data-linked=\"Edison says fire investigations now include possible role of its facilities\" data-tweet=\"$EIX - Edison says fire investigations now include possible role of its facilities https://seekingalpha.com/news/3317770-edison-says-fire-investigations-now-include-possible-role-of-facilities?source=tweet\" data-url=\"https://seekingalpha.com/news/3317770-edison-says-fire-investigations-now-include-possible-role-of-facilities\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:23 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317762\" data-ts=\"1513090772\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/URBN\" target=\"_blank\">URBN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317762-urban-outfitters-higher-after-q4-update\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Urban Outfitters higher after Q4 update</a></h4><ul> <li>Urban Outfitters (<a href='https://seekingalpha.com/symbol/URBN' title='Urban Outfitters, Inc.'>URBN</a> <font color='green'>+2.1%</font>) discloses in a SEC filing that Q4 comparable retail segment sales are up at a mid single-digit rate so far.</li> <li>The retailer isn't due to to report full results until early March since it just spilled <a href=\"https://seekingalpha.com/news/3313623-urban-outfitters-rallies-earnings\" target=\"_blank\">Q3</a> numbers a few weeks ago.</li> <li><a href=\"https://www.sec.gov/Archives/edgar/data/912615/000156459017024798/urbn-10q_20171031.htm\" target=\"_blank\">SEC Form 10-Q</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3317762\" data-linked=\"Urban Outfitters higher after Q4 update\" data-tweet=\"$URBN - Urban Outfitters higher after Q4 update https://seekingalpha.com/news/3317762-urban-outfitters-higher-after-q4-update?source=tweet\" data-url=\"https://seekingalpha.com/news/3317762-urban-outfitters-higher-after-q4-update\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:59 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317753\" data-ts=\"1513088954\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TRN\" target=\"_blank\">TRN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317753-trinity-industries-to-spin-off-infrastructure-businesses-hikes-buyback-program\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Trinity Industries to spin off infrastructure businesses; hikes buyback program</a></h4><ul>     <li>Trinity Industries (NYSE:<a href='https://seekingalpha.com/symbol/TRN' title='Trinity Industries Inc.'>TRN</a>)&nbsp;<font color='green'>+3.3%</font> premarket after unveiling plans to <a href=\"https://seekingalpha.com/pr/17024350-trinity-industries-inc-announces-intention-spin-company-s-infrastructure-related-businesses\" target=\"_blank\">spin off its infrastructure related businesses</a>, resulting in two separate public companies:&nbsp;TRN will operate rail leasing, manufacturing and services business, and a separate company will be focused on infrastructure.</li><li>TRN says \"establishing two separate, independently focused public       companies will allow each company to more closely align its strategic       objectives and capital allocation priorities.\"</li><li>TRN also says it will double its stock repurchase authorization to $500M.</li></ul><div class=\"tiny-share-widget\" data-id=\"3317753\" data-linked=\"Trinity Industries to spin off infrastructure businesses; hikes buyback program\" data-tweet=\"$TRN - Trinity Industries to spin off infrastructure businesses; hikes buyback program https://seekingalpha.com/news/3317753-trinity-industries-to-spin-off-infrastructure-businesses-hikes-buyback-program?source=tweet\" data-url=\"https://seekingalpha.com/news/3317753-trinity-industries-to-spin-off-infrastructure-businesses-hikes-buyback-program\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:29 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317751\" data-ts=\"1513088707\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BSX\" target=\"_blank\">BSX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317751-fda-oks-boston-scis-deep-brain-stimulation-system-shares-ahead-2-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA OKs Boston Sci&#39;s deep brain stimulation system; shares ahead 2% premarket</a></h4><ul><li>Boston Scientific (NYSE:<a href='https://seekingalpha.com/symbol/BSX' title='Boston Scientific Corporation'>BSX</a>) is up&nbsp;<font color='green'>2%</font>&nbsp;premarket on light volume on the news that the FDA has <a href=\"https://seekingalpha.com/pr/17023881-boston-scientific-receives-u-s-fda-approval-vercise-deep-brain-stimulation-system\" target=\"_blank\">approved </a>its Vercise Deep Brain Stimulation System for the treatment of Parkinson's disease &#40;PD&#41;.</li><li>The data supporting the application was generated in a study called <a href=\"https://clinicaltrials.gov/ct2/show/NCT01839396?titles=intrepid&amp;spons=boston+scientific&amp;rank=1\" target=\"_blank\">INTREPID</a> that showed the device delivered good symptom control in PD patients during waking hours. Results from the study should be released in 2018.</li></ul><div class=\"tiny-share-widget\" data-id=\"3317751\" data-linked=\"FDA OKs Boston Sci&#39;s deep brain stimulation system; shares ahead 2% premarket\" data-tweet=\"$BSX - FDA OKs Boston Sci&#39;s deep brain stimulation system; shares ahead 2% premarket https://seekingalpha.com/news/3317751-fda-oks-boston-scis-deep-brain-stimulation-system-shares-ahead-2-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3317751-fda-oks-boston-scis-deep-brain-stimulation-system-shares-ahead-2-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:25 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317748\" data-ts=\"1513088295\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ACER\" target=\"_blank\">ACER</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317748-acer-prices-equity-offering-shares-down-12-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Acer prices equity offering, shares down 12% premarket</a></h4><ul><li>Acer Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/ACER' title='Acer Therapeutics Inc.'>ACER</a>) <a href=\"https://seekingalpha.com/pr/17024661-acer-therapeutics-announces-pricing-underwritten-public-offering-common-stock\" target=\"_blank\">prices </a>its public offering of 916,667 shares of common stock at $12 per share. Underwriters over-allotment is an additional 137.5K shares. Closing date is December 14.</li><li>Shares are down&nbsp;<font color='red'>12%</font>&nbsp;premarket on light volume.</li><li>Yesterday's close was $14.15.</li></ul><div class=\"tiny-share-widget\" data-id=\"3317748\" data-linked=\"Acer prices equity offering, shares down 12% premarket\" data-tweet=\"$ACER - Acer prices equity offering, shares down 12% premarket https://seekingalpha.com/news/3317748-acer-prices-equity-offering-shares-down-12-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3317748-acer-prices-equity-offering-shares-down-12-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:18 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317744\" data-ts=\"1513088081\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MYOK\" target=\"_blank\">MYOK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317744-premarket-analyst-action-healthcare\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket analyst action - healthcare</a></h4><ul><li>MyoKardia (NASDAQ:<a href='https://seekingalpha.com/symbol/MYOK' title='MyoKardia'>MYOK</a>) initiated with Overweight rating and $54 (37% upside) price target by JPMorgan.</li><li>Impax Laboratories (IPXL) initiated with Neutral rating by Guggenheim.</li><li>Endo International (NASDAQ:<a href='https://seekingalpha.com/symbol/ENDP' title='Endo International plc'>ENDP</a>) initiated with Neutral rating by Guggenheim.</li><li>Mylan N.V. (NASDAQ:<a href='https://seekingalpha.com/symbol/MYL' title='Mylan Inc'>MYL</a>) initiated with Buy rating and $59 (49% upside) price target by Guggenheim.</li><li>Teva Pharmaceutical Industries (NYSE:<a href='https://seekingalpha.com/symbol/TEVA' title='Teva Pharmaceutical Industries Limited'>TEVA</a>) initiated with Neutral rating by Guggenheim.</li><li>Sc Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/SCPH' title='scPharmaceuticals Inc.'>SCPH</a>) initiated with Buy rating and $23 (54% upside) price target by Jefferies.</li><li>Endologix (NASDAQ:<a href='https://seekingalpha.com/symbol/ELGX' title='Endologix Inc'>ELGX</a>) resumed with Overweight rating by Piper Jaffray.</li><li>Medtronic (NYSE:<a href='https://seekingalpha.com/symbol/MDT' title='Medtronic plc'>MDT</a>) upgraded to Buy by Argus Research.</li><li>DaVita (NYSE:<a href='https://seekingalpha.com/symbol/DVA' title='DaVita HealthCare Partners Inc.'>DVA</a>) upgraded to Outperform with an $82 (18% upside) price target by Robert Baird.</li><li>Abbott (NYSE:<a href='https://seekingalpha.com/symbol/ABT' title='Abbott Laboratories'>ABT</a>) upgraded to Outperform by BMO Capital Markets.</li><li>Spark Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/ONCE' title='Spark Therapeutics'>ONCE</a>) downgraded to Market Perform by Leerink. Downgraded to Neutral by UBS.</li><li>Juno Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/JUNO' title='Juno Therapeutics'>JUNO</a>) downgraded to Market Perform by Wells Fargo.</li><li>Aetna (NYSE:<a href='https://seekingalpha.com/symbol/AET' title='Aetna, Inc.'>AET</a>) removed from Focus List at Citigroup.</li><li>Source: Bloomberg</li></ul><div class=\"tiny-share-widget\" data-id=\"3317744\" data-linked=\"Premarket analyst action - healthcare\" data-tweet=\"$MYOK $MYOK $AMRX - Premarket analyst action - healthcare https://seekingalpha.com/news/3317744-premarket-analyst-action-healthcare?source=tweet\" data-url=\"https://seekingalpha.com/news/3317744-premarket-analyst-action-healthcare\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:14 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317743\" data-ts=\"1513087931\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317743-premarket-losers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Losers as of 9:05 am</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/CYCC' title='Cyclacel Pharmaceuticals, Inc.'>CYCC</a> <font color='red'>-13%</font>.</li><li><a href='https://seekingalpha.com/symbol/YTEN' title='Yield10 Bioscience, Inc.'>YTEN</a> <font color='red'>-10%</font>.</li><li><a href='https://seekingalpha.com/symbol/MARA' title='Marathon Patent Group, Inc.'>MARA</a>&nbsp;<font color='red'>-7%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3317691-bitcoin-strong-action-alts-litecoin-triples-since-last-week\" target=\"_blank\">Bitcoin</a> boom.</li><li><a href='https://seekingalpha.com/symbol/CASY' title='Casey&#39;s General Stores, Inc.'>CASY</a>&nbsp;<font color='red'>-7%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3317596-caseys-general-stores-misses-0_12-misses-revenue\" target=\"_blank\">Q2 earnings</a>.</li><li><a href='https://seekingalpha.com/symbol/OHRP' title='Ohr Pharmaceutical, Inc.'>OHRP</a> <font color='red'>-6%</font>.</li><li><a href='https://seekingalpha.com/symbol/NCS' title='NCI Building Systems Inc.'>NCS</a> <font color='red'>-6%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/17024136-nci-building-systems-announces-pricing-secondary-offering-investment-funds-associated-clayton\" target=\"_blank\">pricing</a> secondary offering.</li><li><a href='https://seekingalpha.com/symbol/OAS' title='Oasis Petroleum Inc.'>OAS</a>&nbsp;<font color='red'>-6%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3317605-oasis-petroleum-buys-20k-delaware-basin-acres-946m\" target=\"_blank\">acquiring</a> 20.3K acres in the Delaware Basin for $946M.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3317743\" data-linked=\"Premarket Losers as of 9:05 am\" data-tweet=\"$CYCC $YTEN $MARA - Premarket Losers as of 9:05 am https://seekingalpha.com/news/3317743-premarket-losers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3317743-premarket-losers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:12 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317742\" data-ts=\"1513087917\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317742-premarket-gainers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers as of 9:05 am</a></h4><ul> <li><a href='https://seekingalpha.com/symbol/PTI' title='Proteostasis Therapeutics'>PTI</a> <font color='green'>+118%</font> on <a href=\"https://seekingalpha.com/news/3317684-proteostasis-advances-cystic-fibrosis-pipeline-shares-ahead-59-percent-premarket\" target=\"_blank\">positive results</a> across its three cystic fibrosis (NYSE:<a href='https://seekingalpha.com/symbol/CF' title='CF Industries Holdings, Inc.'>CF</a>) pipeline programs.</li><li><a href='https://seekingalpha.com/symbol/GLYC' title='GlycoMimetics'>GLYC</a> <font color='green'>+27%</font> on <a href=\"https://seekingalpha.com/news/3317699-glycomimetics-gmiminus-1271-shows-positive-effect-phase-1-2-aml-study-shares-ahead-24-percent\" target=\"_blank\">positive results</a> from a Phase 1/2 clinical trial assessing GMI-1271.</li><li><a href='https://seekingalpha.com/symbol/RIOT' title='Riot Blockchain, Inc.'>RIOT</a> <font color='green'>+14%</font> on <a href=\"https://seekingalpha.com/news/3317691-bitcoin-strong-action-alts-litecoin-triples-since-last-week\" target=\"_blank\">cryptocurrency jump</a>.</li><li><a href='https://seekingalpha.com/symbol/NVFY' title='Nova Lifestyle, Inc.'>NVFY</a> <font color='green'>+12</font> on <a href=\"https://seekingalpha.com/news/3317708-nova-lifestyle-announces-5m-share-repurchase-program\" target=\"_blank\">share buyback</a>.</li><li><a href='https://seekingalpha.com/symbol/XNET' title='Xunlei Limited'>XNET</a> <font color='green'>+8%</font> on <a href=\"https://seekingalpha.com/news/3317691-bitcoin-strong-action-alts-litecoin-triples-since-last-week\" target=\"_blank\">cryptocurrency jump</a>.</li><li><a href='https://seekingalpha.com/symbol/SSC-OLD' title='Seven Stars Cloud Group, Inc.'>SSC-OLD</a> <font color='green'>+8%</font> on <a href=\"https://seekingalpha.com/news/3317691-bitcoin-strong-action-alts-litecoin-triples-since-last-week\" target=\"_blank\">cryptocurrency jump</a>.</li><li><a href='https://seekingalpha.com/symbol/OSTK' title='Overstock.com, Inc.'>OSTK</a> <font color='green'>+7%</font> on <a href=\"https://seekingalpha.com/news/3317691-bitcoin-strong-action-alts-litecoin-triples-since-last-week\" target=\"_blank\">cryptocurrency jump</a>.</li><li><a href='https://seekingalpha.com/symbol/HMNY' title='Helios and Matheson Analytics, Inc.'>HMNY</a> <font color='green'>+14%</font>.</li><li><a href='https://seekingalpha.com/symbol/MUX' title='McEwen Mining Inc.'>MUX</a> <font color='green'>+6%</font>.</li><li><a href='https://seekingalpha.com/symbol/NETE' title='Net Element International, Inc.'>NETE</a> <font color='green'>+6%</font>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3317742\" data-linked=\"Premarket Gainers as of 9:05 am\" data-tweet=\"$PTI $CF $GLYC - Premarket Gainers as of 9:05 am https://seekingalpha.com/news/3317742-premarket-gainers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3317742-premarket-gainers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:11 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317737\" data-ts=\"1513087314\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PTLA\" target=\"_blank\">PTLA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317737-portola-not-quite-european-marketing-application-for-betrixaban-shares-down-3-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Portola not quite there with European marketing application for betrixaban; shares down 3% premarket</a></h4><ul><li>Portola Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/PTLA' title='Portola Pharmaceuticals'>PTLA</a>) <a href=\"https://seekingalpha.com/pr/17024465-portola-pharmaceuticals-provides-update-european-marketing-authorization-application\" target=\"_blank\">reports </a>that the EMA's advisory group, the Committee for Medicinal Products for Human Use &#40;CHMP&#41;, has requested additional information pertaining to its marketing application for betrixaban.</li><li>The next available submission window is January 23, 2018 so a decision by CHMP will be late Q1. The company says it should be able to address the request with existing clinical data.</li><li>The FDA approved betrixaban, branded as Bevyxxa, in June.</li><li>Shares are down&nbsp;<font color='red'>3%</font>&nbsp;premarket but only on 334 shares.</li></ul><div class=\"tiny-share-widget\" data-id=\"3317737\" data-linked=\"Portola not quite there with European marketing application for betrixaban; shares down 3% premarket\" data-tweet=\"$PTLA - Portola not quite there with European marketing application for betrixaban; shares down 3% premarket https://seekingalpha.com/news/3317737-portola-not-quite-european-marketing-application-for-betrixaban-shares-down-3-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3317737-portola-not-quite-european-marketing-application-for-betrixaban-shares-down-3-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:01 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317732\" data-ts=\"1513086771\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DXTR\" target=\"_blank\">DXTR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317732-dextera-surgical-files-chapter-11\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dextera Surgical files Chapter 11</a></h4><ul><li>Dextera Surgical (<a href='https://seekingalpha.com/symbol/DXTR' title='Dextera Surgical Inc.'>OTC:DXTR</a>) has filed for <a href=\"https://seekingalpha.com/pr/17024475-dextera-surgical-files-chapter-11-bankruptcy-signs-asset-purchase-agreement-aesculap-inc\" target=\"_blank\">Chapter 11 bankruptcy protection</a> as it executes an asset sale to B. Braun's Aesculap for $17.3M. Shares will resume trading at 9:00 am ET.</li></ul><div class=\"tiny-share-widget\" data-id=\"3317732\" data-linked=\"Dextera Surgical files Chapter 11\" data-tweet=\"$DXTR - Dextera Surgical files Chapter 11 https://seekingalpha.com/news/3317732-dextera-surgical-files-chapter-11?source=tweet\" data-url=\"https://seekingalpha.com/news/3317732-dextera-surgical-files-chapter-11\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:52 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317729\" data-ts=\"1513086636\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NVDA\" target=\"_blank\">NVDA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317729-nvidia-down-after-ex-facebook-exec-implies-caution\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nvidia down after ex-Facebook exec implies caution</a></h4><ul><li>        Nvidia (NASDAQ:<a href='https://seekingalpha.com/symbol/NVDA' title='NVIDIA Corporation'>NVDA</a>) shares are&nbsp;<font color='red'>down 1.2%&nbsp;</font>premarket after a <a href=\"http://www.briefing.com/DisplayArticle/ArticlePopup.aspx?ArticleId=IN20171212083026NVDA\" target=\"_blank\">CNBC appearance</a> by ex-Facebook exec Chamath Palihapitiya.</li><li>               Palihapitiya implied caution on Nvidia due to increasing competition in AI hardware as all the large tech &ldquo;hyper-scalers&rdquo; move into AI.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3317281-cnbc-musk-confirms-tesla-making-ai-hardware\" target=\"_blank\">CNBC: Musk confirms Tesla making AI hardware</a> (Dec. 8)</li></ul><div class=\"tiny-share-widget\" data-id=\"3317729\" data-linked=\"Nvidia down after ex-Facebook exec implies caution\" data-tweet=\"$NVDA - Nvidia down after ex-Facebook exec implies caution https://seekingalpha.com/news/3317729-nvidia-down-after-ex-facebook-exec-implies-caution?source=tweet\" data-url=\"https://seekingalpha.com/news/3317729-nvidia-down-after-ex-facebook-exec-implies-caution\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:50 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>79&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317728\" data-ts=\"1513086395\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UHS\" target=\"_blank\">UHS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317728-citi-bullish-on-hospital-operators\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Citi bullish on hospital operators</a></h4><ul><li>In a note, Citigroup upgrades hospital operators Universal Health Services (NYSE:<a href='https://seekingalpha.com/symbol/UHS' title='Universal Health Services Inc.'>UHS</a>) and Tenet Healthcare to Buy citing a more favorable outlook on the industry based on stabilized patient volumes and \"some level of bounce\" expected in 2018.</li><li>Source: Bloomberg</li><li><a href='https://seekingalpha.com/symbol/HUM' title='Humana Inc.'>HUM</a> <a href='https://seekingalpha.com/symbol/HCA' title='HCA Holdings, Inc.'>HCA</a> <a href='https://seekingalpha.com/symbol/CYH' title='Community Health Systems, Inc.'>CYH</a> <a href='https://seekingalpha.com/symbol/LPNT' title='LifePoint Health, Inc.'>LPNT</a> <a href='https://seekingalpha.com/symbol/QHC' title='Quorum Health Corporation'>QHC</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3317728\" data-linked=\"Citi bullish on hospital operators\" data-tweet=\"$UHS $UHS $HUM - Citi bullish on hospital operators https://seekingalpha.com/news/3317728-citi-bullish-on-hospital-operators?source=tweet\" data-url=\"https://seekingalpha.com/news/3317728-citi-bullish-on-hospital-operators\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:46 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317723\" data-ts=\"1513085629\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BSQR\" target=\"_blank\">BSQR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317723-bsquare-announces-amazon-and-microsoft-integrations\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bsquare announces Amazon and Microsoft integrations</a></h4><ul><li>        IoT solution provider Bsquare (NASDAQ:<a href='https://seekingalpha.com/symbol/BSQR' title='BSQUARE Corporation'>BSQR</a>) <a href=\"https://seekingalpha.com/pr/17024346-bsquare-partners-amazon-microsoft-help-drive-powerful-industrial-iot-data-visualizations\" target=\"_blank\">announces</a> new DataV software integrations with Amazon&rsquo;s QuickSight and Microsoft&rsquo;s Power BI analytics tools.</li><li>               The integrations help customers create quick but powerful cross-system interactive data visualizations and reports. &nbsp;&nbsp;</li><li>               Bsquare shares are&nbsp;<font color='green'>up 1.1%</font>&nbsp;premarket.&nbsp;&nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3317723\" data-linked=\"Bsquare announces Amazon and Microsoft integrations\" data-tweet=\"$BSQR - Bsquare announces Amazon and Microsoft integrations https://seekingalpha.com/news/3317723-bsquare-announces-amazon-and-microsoft-integrations?source=tweet\" data-url=\"https://seekingalpha.com/news/3317723-bsquare-announces-amazon-and-microsoft-integrations\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:33 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317717\" data-ts=\"1513085362\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OMER\" target=\"_blank\">OMER</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317717-fda-oks-pediatric-use-for-omeros-omidria-shares-ahead-10-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA OKs pediatric use for Omeros&#39; Omidria; shares ahead 10% premarket</a></h4><ul><li>Omeros (NASDAQ:<a href='https://seekingalpha.com/symbol/OMER' title='Omeros Corporation'>OMER</a>) is up&nbsp;<font color='green'>10%</font>&nbsp;premarket on light volume in response to the <a href=\"https://seekingalpha.com/pr/17024181-omeros-corporation-announces-fda-approval-omidria-use-pediatric-patients\" target=\"_blank\">news</a> that the FDA has approved the use of <a href=\"http://www.omidria.com/\" target=\"_blank\">OMIDRIA </a>(phenylephrine and ketorolac intraocular solution) in pediatric patients, infants through age 17.</li><li>OMIDRIA is used to prevent pupil constriction and reduce postoperative pain in patients undergoing cataract surgery or the replacement of an intraocular lens. It was approved in the U.S. for adult patients in June 2014.</li></ul><div class=\"tiny-share-widget\" data-id=\"3317717\" data-linked=\"FDA OKs pediatric use for Omeros&#39; Omidria; shares ahead 10% premarket\" data-tweet=\"$OMER - FDA OKs pediatric use for Omeros&#39; Omidria; shares ahead 10% premarket https://seekingalpha.com/news/3317717-fda-oks-pediatric-use-for-omeros-omidria-shares-ahead-10-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3317717-fda-oks-pediatric-use-for-omeros-omidria-shares-ahead-10-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:29 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>16&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317705\" data-ts=\"1513084795\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AQXP\" target=\"_blank\">AQXP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317705-aquinox-pharma-up-16-premarket-on-fda-advisory-committee-vote-on-ic-bps-studies\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aquinox Pharma up 16% premarket on FDA advisory committee vote on IC/BPS studies</a></h4><ul><li>Aquinox Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/AQXP' title='Aquinox Pharmaceuticals, Inc.'>AQXP</a>) is up&nbsp;<font color='green'>16%</font>&nbsp;premarket, albeit on only 400 shares, in response to yesterday's unanimous vote by an FDA advisory committee in favor of combining patients with interstitial cystitis &#40;IC&#41; and patients with bladder pain syndrome &#40;BPS&#41; in clinical trials. The vote was aligned with the current guideline from the American Urological Association and the <a href=\"https://seekingalpha.com/pr/17021980-aquinox-statement-fda-advisory-committee-meeting-discuss-interstitial-cystitis-bladder-pain\" target=\"_blank\">company's position</a>.</li><li>A Phase 3 clinical trial, <a href=\"https://clinicaltrials.gov/ct2/show/NCT02858453?term=aquinox&amp;rank=5\" target=\"_blank\">LEADERSHIP 301</a>, assessing lead candidate AQX-1125 for reducing pain in IC/BPS patients is ongoing. Topline data should be available in Q3 2018.</li></ul><div class=\"tiny-share-widget\" data-id=\"3317705\" data-linked=\"Aquinox Pharma up 16% premarket on FDA advisory committee vote on IC/BPS studies\" data-tweet=\"$AQXP $NLTX - Aquinox Pharma up 16% premarket on FDA advisory committee vote on IC/BPS studies https://seekingalpha.com/news/3317705-aquinox-pharma-up-16-premarket-on-fda-advisory-committee-vote-on-ic-bps-studies?source=tweet\" data-url=\"https://seekingalpha.com/news/3317705-aquinox-pharma-up-16-premarket-on-fda-advisory-committee-vote-on-ic-bps-studies\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:19 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317715\" data-ts=\"1513084791\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FMSA\" target=\"_blank\">FMSA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317715-fairmount-santrol-unimin-to-merge-in-cash-and-stock-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fairmount Santrol, Unimin to merge in cash and stock deal</a></h4><ul>     <li>Fairmount Santrol (NYSE:<a href='https://seekingalpha.com/symbol/FMSA' title='Fairmount Santrol, Inc.'>FMSA</a>) <font color='green'>+5.2%</font> premarket after SCR&nbsp;Sibelco subsidiary Unimin <a href=\"https://seekingalpha.com/pr/17024191-fairmount-santrol-unimin-merge-creating-leader-proppant-industrial-materials-solutions\" target=\"_blank\">agrees to acquire</a> the frac sand company in a cash and stock deal.</li>     <li>Under the merger terms, FMSA shareholders will receive $170M in cash, or ~$0.74/share, and will own 35% of the combined company, with Sibelco owning the remaining 65%.</li>     <li>The new company, to be listed on the NYSE, will  create an industry-leading proppant and industrial  materials solutions provider expected to have 45M tons of  annual sand and mineral processing capacity and 3M tons of  annual coating capacity, plus a comprehensive logistics platform with a large-scale terminal network across North America.</li>     <li>On a pro forma basis, revenue for the new company would have totaled ~$2B with adjusted EBITDA of ~$400M, excluding anticipated synergies, for the 12 months ending Sept. 30.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3317715\" data-linked=\"Fairmount Santrol, Unimin to merge in cash and stock deal\" data-tweet=\"$FMSA - Fairmount Santrol, Unimin to merge in cash and stock deal https://seekingalpha.com/news/3317715-fairmount-santrol-unimin-to-merge-in-cash-and-stock-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3317715-fairmount-santrol-unimin-to-merge-in-cash-and-stock-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:19 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>47&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317699\" data-ts=\"1513083482\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GLYC\" target=\"_blank\">GLYC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317699-glycomimetics-gmiminus-1271-shows-positive-effect-in-phase-1-2-aml-study-shares-ahead-24\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GlycoMimetics&#39; GMI-1271 shows positive effect in Phase 1/2 AML study; shares ahead 24% premarket</a></h4><ul><li>GlycoMimetics (NASDAQ:<a href='https://seekingalpha.com/symbol/GLYC' title='GlycoMimetics'>GLYC</a>) is up&nbsp;<font color='green'>24%</font>&nbsp;premarket on modestly higher volume on the heels of its <a href=\"https://seekingalpha.com/pr/17024178-glycomimetics-reports-improvements-median-overall-survival-versus-historical-matched-controls\" target=\"_blank\">announcement </a>of positive results from a Phase 1/2 clinical trial assessing GMI-1271 in patients with relapsed/refractory acute myeloid leukemia &#40;AML&#41; and in older patients with newly diagnosed AML. Ther data were presented at ASH in Atlanta.</li><li>In 54 patients with relapsed/refractory AML who received the Phase 2 dose (median follow-up of 6.6 months), the clinical remission rate was 43% (n=23/54). Median overall survival &#40;OS&#41; was 9.4 months while median duration of remission was 11.1 months.</li><li>In 25 older patients with newly diagnosed AML (median follow-up of 10.5 months), the clinical remission rate was 68% (n=17/25). Median OS was 15.8 months while median duration of remission was 14.8 months. Median event-free survival was 11.3 months.</li><li>GMI-1271 was generally well-tolerated. There was a 3% rate of severe, debilitating oral mucositis, well below the historical rate of 20 - 25%.</li><li>A Phase 3 study should commence in mid-2018.</li><li><a href=\"http://glycomimetics.com/pipeline-technology/product-portfolio/gmi-1271/\" target=\"_blank\">GMI-1271</a> is an E-selectin antagonist which disrupts known pathways of tumor resistance which improves the effectiveness of chemotherapy.</li></ul><div class=\"tiny-share-widget\" data-id=\"3317699\" data-linked=\"GlycoMimetics&#39; GMI-1271 shows positive effect in Phase 1/2 AML study; shares ahead 24% premarket\" data-tweet=\"$GLYC - GlycoMimetics&#39; GMI-1271 shows positive effect in Phase 1/2 AML study; shares ahead 24% premarket https://seekingalpha.com/news/3317699-glycomimetics-gmiminus-1271-shows-positive-effect-in-phase-1-2-aml-study-shares-ahead-24?source=tweet\" data-url=\"https://seekingalpha.com/news/3317699-glycomimetics-gmiminus-1271-shows-positive-effect-in-phase-1-2-aml-study-shares-ahead-24\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:58 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317695\" data-ts=\"1513082587\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IMPV\" target=\"_blank\">IMPV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317695-jpmorgan-downgrades-imperva-and-adobe\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">JPMorgan downgrades Imperva and Adobe</a></h4><ul><li>        JPMorgan <a href=\"https://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;source=web&amp;cd=4&amp;cad=rja&amp;uact=8&amp;ved=0ahUKEwiV1tyavoTYAhUp04MKHS-aD2UQFgg1MAM&amp;url=https%3A%2F%2Fwww.streetinsider.com%2FAnalyst%2BPT%2BChange%2FJPMorgan%2BDowngrades%2BImperva%2B%28IMPV%29%2Bto%2BUnderweight%2F13590772.html&amp;usg=AOvVaw13F1l5WU7bENaqvc9ULuLD\" target=\"_blank\">downgrades</a> Imperva (NASDAQ:<a href='https://seekingalpha.com/symbol/IMPV' title='Imperva, Inc.'>IMPV</a>) from Neutral to Underweight and lowers the price target from $54 to $45. &nbsp;</li><li>        The firm also <a href=\"https://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;source=web&amp;cd=1&amp;cad=rja&amp;uact=8&amp;ved=0ahUKEwjPw6r1voTYAhWD8YMKHf-mBTgQFggnMAA&amp;url=https%3A%2F%2Fwww.streetinsider.com%2FAnalyst%2BComments%2FJPMorgan%2BDowngrades%2BAdobe%2B%28ADBE%29%2Bto%2BNeutral%2F13590753.html&amp;usg=AOvVaw1iHxjTMb_4qF2Rz8wi4diD\" target=\"_blank\">downgrades</a> Adobe (NASDAQ:<a href='https://seekingalpha.com/symbol/ADBE' title='Adobe Systems Incorporated'>ADBE</a>) from Overweight to Neutral with a $185 price target. Firm steps to the side citing Adobe&rsquo;s valuation compared to its peers.</li><li>               Adobe shares are&nbsp;<font color='red'>down 0.8%</font>&nbsp;premarket.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3317695\" data-linked=\"JPMorgan downgrades Imperva and Adobe\" data-tweet=\"$IMPV $IMPV $ADBE - JPMorgan downgrades Imperva and Adobe https://seekingalpha.com/news/3317695-jpmorgan-downgrades-imperva-and-adobe?source=tweet\" data-url=\"https://seekingalpha.com/news/3317695-jpmorgan-downgrades-imperva-and-adobe\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:43 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317688\" data-ts=\"1513082314\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TNXP\" target=\"_blank\">TNXP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317688-tonix-pharmaceuticals-completes-positive-pre-ind-meeting-fda-for-tnxminus-102-sl-shares-ahead\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tonix Pharmaceuticals completes positive pre-IND meeting with FDA for TNX-102 SL; shares ahead 15% premarket</a></h4><ul><li>Tonix Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/TNXP' title='Tonix Pharmaceuticals Holding Corp.'>TNXP</a>) <a href=\"https://seekingalpha.com/pr/17024193-tonix-pharmaceuticals-completes-positive-pre-ind-meeting-fda-tnxminus-102-sl-cyclobenzaprine\" target=\"_blank\">announces</a> that it recently held a pre-Investigational New Drug &#40;IND&#41; meeting with the FDA to discuss its proposed development of TNX-102 SL for bedtime use for the treatment of agitation in Alzheimer&rsquo;s disease &#40;AAD&#41;.</li><li>TNX-102 SL&nbsp;IND for AAD is expected to be submitted in Q1 2018.</li>     <li>TNX-102 SL is a patented sublingual tablet formulation of cyclobenzaprine hydrochloride which provides rapid transmucosal absorption.</li><li>Shares are up&nbsp;<font color='green'>15%</font>&nbsp;premarket on light volume.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3317688\" data-linked=\"Tonix Pharmaceuticals completes positive pre-IND meeting with FDA for TNX-102 SL; shares ahead 15% premarket\" data-tweet=\"$TNXP - Tonix Pharmaceuticals completes positive pre-IND meeting with FDA for TNX-102 SL; shares ahead 15% premarket https://seekingalpha.com/news/3317688-tonix-pharmaceuticals-completes-positive-pre-ind-meeting-fda-for-tnxminus-102-sl-shares-ahead?source=tweet\" data-url=\"https://seekingalpha.com/news/3317688-tonix-pharmaceuticals-completes-positive-pre-ind-meeting-fda-for-tnxminus-102-sl-shares-ahead\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:38 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317684\" data-ts=\"1513082156\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PTI\" target=\"_blank\">PTI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317684-proteostasis-advances-cystic-fibrosis-pipeline-shares-ahead-59-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Proteostasis advances cystic fibrosis pipeline; shares ahead 59% premarket</a></h4><ul><li>Thinly traded nano cap Proteostasis Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/PTI' title='Proteostasis Therapeutics'>PTI</a>) is up&nbsp;<font color='green'>59%</font>&nbsp;premarket on light volume in response to its <a href=\"https://seekingalpha.com/pr/17023808-proteostasis-therapeutics-announces-positive-clinical-results-studies-ptiminus-428-ptiminus\" target=\"_blank\">announcement </a>of positive results across its three cystic fibrosis &#40;CF&#41; pipeline programs.</li><li>A Phase 2 study assessing 50 mg of lead candidate PTI-428 once daily for 28 days in CF patients on a background of Vertex Pharmaceuticals' (NASDAQ:<a href='https://seekingalpha.com/symbol/VRTX' title='Vertex Pharmaceuticals Incorporated'>VRTX</a>) ORKAMBI (lumacaftor/ivacaftor) showed average absolute improvements in lung function (ppFEV1) of 5.2% from baseline compared to placebo (p&lt;0.05) and average relative improvements of 9.2% (p&lt;0.05). The treatment effect was achieved by day 14 and maintained through day 28.</li><li>PTI-428, a CFTR amplifier, was safe and well-tolerated with no clinically meaningful interaction with lumacaftor/ivacaftor. There were two discontinuations, both mild grade thrombocytopenia, one on ORKAMBI alone and one on PTI-428. Both resolved spontaneously.</li><li>Initial data from a 14-day study of 100 mg of PTI-801 once daily in four CF patients on background ORKAMBI showed a similar pharmacokinetic profile to healthy volunteers. There were no clinically meaningful drug-drug interactions with lumacaftor or ivacaftor. Average absolute improvements in lung function (ppFEV1) were ~4% from baseline while average relative improvements were ~7% after two weeks of dosing. Enrollment of 20 patients should be completed next quarter. PTI-801 is a CFTR corrector.</li><li>A study of PTI-808, a CFTR potentiator, in 48 healthy volunteers showed favorable safety and pharmacokinetic profiles.</li><li>Co-administration of PTI-428, PTI-808 and PTI-801 in 20 healthy volunteers has been completed. The safety profile was favorable and supports potential once daily dosing.</li></ul><div class=\"tiny-share-widget\" data-id=\"3317684\" data-linked=\"Proteostasis advances cystic fibrosis pipeline; shares ahead 59% premarket\" data-tweet=\"$PTI $PTI $VRTX - Proteostasis advances cystic fibrosis pipeline; shares ahead 59% premarket https://seekingalpha.com/news/3317684-proteostasis-advances-cystic-fibrosis-pipeline-shares-ahead-59-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3317684-proteostasis-advances-cystic-fibrosis-pipeline-shares-ahead-59-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:35 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317693\" data-ts=\"1513081957\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/COTY\" target=\"_blank\">COTY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317693-coty-jumps-after-citi-upgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Coty jumps after Citi upgrade</a></h4><ul> <li>Citi dips into the beauty products sector to upgrade Coty (NYSE:<a href='https://seekingalpha.com/symbol/COTY' title='Coty Inc.'>COTY</a>) to a Buy rating after having it locked in at Neutral.</li> <li>The firm expects investor sentiment to turn around on Coty to push up the earnings multiple.</li> <li>The new price target of <a href=\"https://www.streetinsider.com/Analyst+Comments/UPDATE%3A+Citi+Upgrades+Coty+Inc.+%28COTY%29+to+Buy%2C+Shorts+Will+Cover+as+CoverGirl+Relaunches/13590891.html\" target=\"_blank\">$21</a>&nbsp;from the Citi team reps 17% upside potential.</li> <li>Shares of Coty are <font color='green'>up 3.24%</font> in premarket trading tp $18.49.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3317693\" data-linked=\"Coty jumps after Citi upgrade\" data-tweet=\"$COTY - Coty jumps after Citi upgrade https://seekingalpha.com/news/3317693-coty-jumps-after-citi-upgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3317693-coty-jumps-after-citi-upgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:32 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317691\" data-ts=\"1513081830\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GBTC\" target=\"_blank\">GBTC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317691-bitcoin-strong-action-is-in-alts-litecoin-triples-since-last-week\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bitcoin strong, but action is in alts - Litecoin triples since last week</a></h4><ul><li>Picking two of the larger-cap alt coins, Litecoin - sometimes referred to as the \"silver\" to Bitcoin's \"gold\" - has&nbsp;<font color='green'>more than tripled</font>&nbsp;since last Thursday. This brings the year-over-year return to more than 8,000%.</li><li>The second-largest market cap coin, Ether is<font color='green'> 25% higher&nbsp;</font>since last Thursday, bringing its Y/Y move to 6,260%.</li><li>At $16,750, Bitcoin is about flat over the past few sessions, and up only a modest 2,050% Y/Y.</li><li>Cryptos have no doubt made many rich, but in the Bitcoin community, it's bad form to show any sign of wealth. <a href=\"https://fee.org/articles/how-to-live-like-a-bitcoin-millionaire/\" target=\"_blank\">Check out Jeff Tucker's</a> \"How to Live Like a Bitcoin Millionaire.\" From the piece ... \"People say that Bitcoin enthusiasts are banking on an illusion. Maybe it is the opposite. Maybe it is they who have finally embraced the core truth that what you spend today only eats up potential wealth tomorrow. After 100 years of bad money, that truth has evaporated from public consciousness. Bitcoin reveals it anew.\"</li><li>Previously: <a href=\"https://seekingalpha.com/news/3317651-sec-warns-cryptos-icos\" target=\"_blank\">SEC warns on cryptos, ICOs</a> (Dec. 12)</li><li>Related tickers: <a href='https://seekingalpha.com/symbol/GBTC' title='Grayscale Bitcoin Trust &#40;BTC&#41;'>OTCQX:GBTC</a>, <a href='https://seekingalpha.com/symbol/COIN' title='Winklevoss Bitcoin Trust ETF'>COIN</a>, <a href='https://seekingalpha.com/symbol/RIOT' title='Riot Blockchain, Inc.'>RIOT</a>, <a href='https://seekingalpha.com/symbol/OSTK' title='Overstock.com, Inc.'>OSTK</a>, <a href='https://seekingalpha.com/symbol/SSC-OLD' title='Seven Stars Cloud Group, Inc.'>SSC-OLD</a>, <a href='https://seekingalpha.com/symbol/MARA' title='Marathon Patent Group, Inc.'>MARA</a>, <a href='https://seekingalpha.com/symbol/UEPS' title='Net 1 UEPS Technologies, Inc.'>UEPS</a>, <a href='https://seekingalpha.com/symbol/BITCF' title='First Bitcoin Capital Corp.'>OTC:BITCF</a>, <a href='https://seekingalpha.com/symbol/XNET' title='Xunlei Limited'>XNET</a>, <a href='https://seekingalpha.com/symbol/GROW' title='U.S. Global Investors, Inc.'>GROW</a>, <a href='https://seekingalpha.com/symbol/BTSC' title='Bitcoin Services, Inc.'>OTCPK:BTSC</a>, <a href='https://seekingalpha.com/symbol/BTCS' title='BTCS Inc.'>OTCQB:BTCS</a>, <a href='https://seekingalpha.com/symbol/MGTI' title='MGT Capital Investments, Inc.'>OTCQB:MGTI</a>, <a href='https://seekingalpha.com/symbol/SRAX' title='Social Reality Inc.'>SRAX</a>, <a href='https://seekingalpha.com/symbol/GAHC' title='Global Arena Holding, Inc.'>OTCPK:GAHC</a>, <a href='https://seekingalpha.com/symbol/UBIA' title='UBI BlockChain Internet Ltd.'>OTC:UBIA</a>, <a href='https://seekingalpha.com/symbol/ARSC' title='American Security Resources Corp.'>OTC:ARSC</a>, <a href='https://seekingalpha.com/symbol/USTC' title='USA Real Estate Holding Co'>OTCPK:USTC</a>, PRELF, <a href='https://seekingalpha.com/symbol/BLKCF' title='Global Blockchain Technologies Corp.'>OTCPK:BLKCF</a>, <a href='https://seekingalpha.com/symbol/CRCW' title='The Crypto Company'>OTC:CRCW</a>, <a href='https://seekingalpha.com/symbol/COINB' title='Coinbase'>COINB</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3317691\" data-linked=\"Bitcoin strong, but action is in alts - Litecoin triples since last week\" data-tweet=\"$GBTC $GBTC $COIN - Bitcoin strong, but action is in alts - Litecoin triples since last week https://seekingalpha.com/news/3317691-bitcoin-strong-action-is-in-alts-litecoin-triples-since-last-week?source=tweet\" data-url=\"https://seekingalpha.com/news/3317691-bitcoin-strong-action-is-in-alts-litecoin-triples-since-last-week\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:30 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>49&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317690\" data-ts=\"1513081648\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TER\" target=\"_blank\">TER</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317690-goldman-sachs-upgrades-teradyne\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Goldman Sachs upgrades Teradyne</a></h4><ul><li>        Goldman Sachs <a href=\"https://www.streetinsider.com/Analyst+PT+Change/Goldman+Sachs+Upgrades+Teradyne+%28TER%29+to+Buy+On+Improved+2018+Semi+Test+Outlook/13590887.html\" target=\"_blank\">upgrades</a> Teradyne (NYSE:<a href='https://seekingalpha.com/symbol/TER' title='Teradyne Inc.'>TER</a>) from Neutral to Buy and raises the price target by $4 to $46.</li><li>               Firm cites improved 2018 outlook for semiconductor tests.&nbsp;</li><li>               Teradyne shares are&nbsp;<font color='green'>up 1.48%</font>&nbsp;premarket.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3317690\" data-linked=\"Goldman Sachs upgrades Teradyne\" data-tweet=\"$TER - Goldman Sachs upgrades Teradyne https://seekingalpha.com/news/3317690-goldman-sachs-upgrades-teradyne?source=tweet\" data-url=\"https://seekingalpha.com/news/3317690-goldman-sachs-upgrades-teradyne\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:27 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317689\" data-ts=\"1513081638\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALV\" target=\"_blank\">ALV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317689-autoliv-to-spin-off-electronics-segment\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Autoliv to spin off electronics segment</a></h4><ul> <li>Autoliv (NYSE:<a href='https://seekingalpha.com/symbol/ALV' title='Autoliv Inc.'>ALV</a>)&nbsp;announces that its board finished a strategic review of the business.</li><li>A decision to spin off the electronics business segment was made by the board to add additional value to shareholders.</li><li>Autoliv says the key drivers for the separation included the different pace of technology advancement in the two businesses and different sales growth rates over the near and long-term with limited customer or operational synergies.</li><li>The spinoff will be effected by a payment of a dividend of the common stock of the new electronics company on a pro rata basis to the holders of common shares.</li><li>ALV  <font color='green'>+1.28%</font> premarket to  $129.39</li><li>Source: <a href=\"https://seekingalpha.com/pr/17024030-autoliv-concludes-strategic-review-prepares-spin-electronics-segment\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3317689\" data-linked=\"Autoliv to spin off electronics segment\" data-tweet=\"$ALV - Autoliv to spin off electronics segment https://seekingalpha.com/news/3317689-autoliv-to-spin-off-electronics-segment?source=tweet\" data-url=\"https://seekingalpha.com/news/3317689-autoliv-to-spin-off-electronics-segment\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:27 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317685\" data-ts=\"1513080924\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SSYS\" target=\"_blank\">SSYS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317685-stratasys-tech-used-aerospace-engineering-company-for-airbus-panels\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Stratasys tech used by aerospace engineering company for Airbus panels</a></h4><ul><li>        Stratasys (NASDAQ:<a href='https://seekingalpha.com/symbol/SSYS' title='Stratasys, Inc.'>SSYS</a>) <a href=\"https://seekingalpha.com/pr/17024034-indaero-secures-new-business-major-airbus-suppliers-transforming-tool-production-using\" target=\"_blank\">announces</a> that aerospace and engineering company Indaero has secured business with several Tier 1 and 2 Airbus suppliers using Stratasys&rsquo; FDM 3D printing for complex tool production.</li><li>               Indaero is an end-to-end supplier of aircraft panels and FDM 3D printing creates lightweight tools that help differentiate the company. &nbsp;&nbsp;</li><li>                Previously: <a href=\"https://seekingalpha.com/news/3314551-stratasys-announces-agreement-philips\" target=\"_blank\">Stratasys announces agreement with Philips</a> (Nov. 27)</li></ul><div class=\"tiny-share-widget\" data-id=\"3317685\" data-linked=\"Stratasys tech used by aerospace engineering company for Airbus panels\" data-tweet=\"$SSYS - Stratasys tech used by aerospace engineering company for Airbus panels https://seekingalpha.com/news/3317685-stratasys-tech-used-aerospace-engineering-company-for-airbus-panels?source=tweet\" data-url=\"https://seekingalpha.com/news/3317685-stratasys-tech-used-aerospace-engineering-company-for-airbus-panels\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:15 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317676\" data-ts=\"1513080045\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AGN\" target=\"_blank\">AGN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317676-allergan-to-acquire-repros-for-0_67-per-share\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Allergan to acquire Repros for $0.67 per share</a></h4><ul><li>Through a subsidiary, Allergan (NYSE:<a href='https://seekingalpha.com/symbol/AGN' title='Allergan plc'>AGN</a>) has agreed to <a href=\"https://seekingalpha.com/pr/17024123-repros-therapeutics-inc-announces-acquisition-allergan-plc\" target=\"_blank\">acquire </a>Repros Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/RPRX' title='Repros Therapeutics Inc.'>RPRX</a>) for $0.67 per share in cash, almost a 43% premium to yesterday's close of $0.47.</li><li>Repros has two products in its pipeline: Enclomiphene citrate for secondary hypogonadism and Proellex (telapristone acetate) for uterine fibroids and endometriosis.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3278869-repros-proellex-program-remain-partial-clinical-hold-pending-compilation-large-safety\" target=\"_blank\">Repros' Proellex program to remain on partial clinical hold pending compilation of large safety database; shares slump 48% premarket</a> (July 17)</li></ul><div class=\"tiny-share-widget\" data-id=\"3317676\" data-linked=\"Allergan to acquire Repros for $0.67 per share\" data-tweet=\"$AGN $AGN $RPRX - Allergan to acquire Repros for $0.67 per share https://seekingalpha.com/news/3317676-allergan-to-acquire-repros-for-0_67-per-share?source=tweet\" data-url=\"https://seekingalpha.com/news/3317676-allergan-to-acquire-repros-for-0_67-per-share\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:00 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":62,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}